# bib

id: cord-293360-nmttgxlq
author: García, Leidy Y.
title: Acceptance of a COVID-19 vaccine: A multifactorial consideration
date: 2020-11-10
extension: .txt
mime: text/plain
words: 520
sentence: 16
flesch: 25
cache: cache/cord-293360-nmttgxlq.txt
txt: txt/cord-293360-nmttgxlq.txt
summary:
  In fact, the preliminary results of a Chilean case study on COVID-19 vaccine perception in the country, with a nationwide representative sample of 1097 individuals, shows that 87% are willing to vaccinate, a relatively high proportion and slightly lower than the rate found by García and Cerda Specifically, the willingness to vaccinate against SARS-CoV-2 depends on: (a) Availability, i.e. the actual existence of an effective vaccine and its country of origin; (b) Access to the vaccine, which could be limited by individual or governmental budgetary restrictions to finance preventive public health measures; (c) Perceived health risk, which depends on the intensity and severity of side effects and COVID-19 prevalence; (d) Information on benefits, risks and access pathways; (e) Previous experience with other vaccines and exposure to diseases, as this affects risk perception; and (f) Sociodemographic factors including age, education level, gender and more.


id: cord-297022-zs5m36cp
author: Kwong, Jeffrey C.
title: Appropriate measures of influenza immunization program effectiveness
date: 2007-01-22
extension: .txt
mime: text/plain
words: 912
sentence: 30
flesch: 37
cache: cache/cord-297022-zs5m36cp.txt
txt: txt/cord-297022-zs5m36cp.txt
summary:
  A better measure of viral activity is the proportion of influenza tests positive (the number of cases of lab-confirmed influenza divided by the number of tests performed). That only 2 cases of influenza per 10,000 people are identified during months of influenza activity, when the actual rates of disease approach 5 per 100 people, further raises concern that any laboratory-derived measures of influenza activity are vulnerable to ascertainment and sampling biases.


id: cord-257533-i85dyg8n
author: Henn, Wolfram
date: 2020-06-23
extension: .txt
mime: text/plain
words: 1071
sentence: 33
flesch: 30
cache: cache/cord-257533-i85dyg8n.txt
txt: txt/cord-257533-i85dyg8n.txt
title:
  Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity

summary:
  but anyway relevant-initial shortage of vaccine supply without creating social discomfort or even unrest. After having overcome the expected initial shortage of vaccines, the global community must take appropriate measures to rapidly generate a worldwide herd immunity against SARS-CoV-2 through implementing mandatory vaccination programs encompassing all countries and age groups.


id: cord-312517-b24zlaqt
author: Kim, Denny
date: 2020-06-19
extension: .txt
mime: text/plain
words: 1950
sentence: 73
flesch: 37
cache: cache/cord-312517-b24zlaqt.txt
txt: txt/cord-312517-b24zlaqt.txt
title:
  The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines

summary:
  DNA vaccines have been under development since the early 1990s. The 2019 proposed revision of the WHO guidelines on DNA vaccines lists the approaches being employed to enhance the immunogenicity of a DNA vaccine [9] .


id: cord-007440-7gcpk9x9
author: Koprowski, Hilary
title: Vaccines and sera through plant biotechnology()
date: 2005-03-07
extension: .txt
mime: text/plain
words: 2113
sentence: 98
flesch: 49
cache: cache/cord-007440-7gcpk9x9.txt
txt: txt/cord-007440-7gcpk9x9.txt
summary:
  However, plant production of vaccines and sera is not a simple procedure with assured success in each undertaking. Codon optimization, careful approaches to harvesting and purifying plant products, use of plant parts such as chloroplasts to increase uptake of the material are but a few potential avenues to help increase the yield of the final product.


id: cord-288038-jdinf8od
author: Thindwa, Deus
date: 2020-06-19
extension: .txt
mime: text/plain
words: 2617
sentence: 84
flesch: 31
cache: cache/cord-288038-jdinf8od.txt
txt: txt/cord-288038-jdinf8od.txt
title:
  Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality

summary:
  Two vaccines that target a large burden of the remaining respiratory disease in older adults are seasonal influenza vaccines and 23-valent pneumococcal polysaccharide vaccine (PPV23). We conducted a non-systematic review of the published, pre-print and grey literature to evaluate whether vaccination of older adults with seasonal influenza vaccine or PPV23 could help reduce COVID-19 mortality.


id: cord-274765-3wzht843
author: Kweon, Chang-Hee
title: Derivation of attenuated porcine epidemic diarrhea virus (PEDV) as vaccine candidate
date: 1999-06-04
extension: .txt
mime: text/plain
words: 2526
sentence: 109
flesch: 51
cache: cache/cord-274765-3wzht843.txt
txt: txt/cord-274765-3wzht843.txt
summary:
  An apparently new syndrome of porcine epidemic diarrhea Some characteristics of a new porcine coronavirus and detection of antigen and antibody by ELISA Experimental infection of pigs with a new porcine enteric coronavirus CV 777 Porcine epidemic diarrhea virus as a cause of persistent diarrhea in a herd of breeding and ®nishing pigs Propagation of the virus of porcine epidemic diarrhea in cell culture Isolation and serial propagation of porcine epidemic diarrhea virus in cell cultures and partial characterization of the isolate Sequence analysis of the porcine epidemic diarrhea virus genome between the nucleocapsid and spike protein genes reveals a polymorphic ORF Rapid diagnosis of porcine epidemic diarrhea virus infection by polymerase chain reaction Porcine parvovirus: properties and prevalence of a strain isolated in the US Procedures for identi®cation of arthropod borne viruses A new in vitro method (END) for detection and measurement of hog cholera virus and its antibody by means of eect of HC virus on newcastle disease virus in swine tissue culture. key: cord-274765-3wzht843 authors: Kweon, Chang-Hee; Kwon, Byung-Joon; Lee, Jae-Gil; Kwon, Geon-Oh; Kang, Yung-Bai title: Derivation of attenuated porcine epidemic diarrhea virus (PEDV) as vaccine candidate date: 1999-06-04 journal: Vaccine DOI: 10.1016/s0264-410x(99)00059-6 sha: doc_id: 274765 cord_uid: 3wzht843 The field isolate of porcine epidemic diarrhea virus (PEDV) was serially passaged in Vero cells.


id: cord-298551-ua90xoak
author: Bennet, Rutger
title: Influenza epidemiology among hospitalized children in Stockholm, Sweden 1998–2014
date: 2016-06-14
extension: .txt
mime: text/plain
words: 3113
sentence: 146
flesch: 45
cache: cache/cord-298551-ua90xoak.txt
txt: txt/cord-298551-ua90xoak.txt
summary:
  key: cord-298551-ua90xoak authors: Bennet, Rutger; Hamrin, Johan; Wirgart, Benita Zweygberg; Östlund, Maria Rotzén; Örtqvist, Åke; Eriksson, Margareta title: Influenza epidemiology among hospitalized children in Stockholm, Sweden 1998–2014 date: 2016-06-14 journal: Vaccine DOI: 10.1016/j.vaccine.2016.04.082 sha: doc_id: 298551 cord_uid: ua90xoak BACKGROUND: Retrospective study of annually collected data of virologically confirmed influenza in hospitalized children 0–17 years living in the catchment area (230,000 children).


id: cord-259299-z3o4t7mz
author: Chinsangaram, Jarasvech
date: 1998-10-31
extension: .txt
mime: text/plain
words: 3332
sentence: 129
flesch: 43
cache: cache/cord-259299-z3o4t7mz.txt
txt: txt/cord-259299-z3o4t7mz.txt
title:
  Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus

summary:
  US Government Printing Office Biochemical identification of viruses causing the 1981 outbreaks of foot-and-mouth disease in the UK Subtyping of European footand-mouth disease virus strains by nucleotide sequence determination The carrier state in foot-and-mouth disease -an immunological review Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate Immunization against virus disease: In contrast to attenuated viruses selected by serial passage which are genetically unstable', deletion of the L protein coding region makes it highly unlikely that the leader proteinasedeficient virus (A12-LLV2) will revert to virulence.


id: cord-256784-wfaqim7d
author: Modjarrad, Kayvon
title: MERS-CoV vaccine candidates in development: The current landscape
date: 2016-06-03
extension: .txt
mime: text/plain
words: 3339
sentence: 122
flesch: 34
cache: cache/cord-256784-wfaqim7d.txt
txt: txt/cord-256784-wfaqim7d.txt
summary:
  Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution Preand postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus Family cluster of Middle East respiratory syndrome coronavirus infections Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients Hospital outbreak of Middle East respiratory syndrome coronavirus Hospital-associated Middle East respiratory syndrome coronavirus infections Hospital-associated Middle East respiratory syndrome coronavirus infections Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health Hendra virus An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels Rapid generation of a mouse model for Middle East respiratory syndrome Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease Animal models of Middle East respiratory syndrome coronavirus infection Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia epidemiological findings from a retrospective investigation East Respiratory Syndrome Coronavirus (MERS-CoV) Summary and Literature Update-as of 11 Update: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea A decade after SARS: strategies for controlling emerging coronaviruses Detection of coronaviruses in bats of various species in Italy Diversity of coronavirus in bats from Eastern Thailand MERS-related betacoronavirus in Vespertilio superans bats Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai Antibodies against MERS coronavirus in dromedary camels MERS coronavirus in dromedary camel herd, Saudi Arabia Evidence for camel-to-human transmission of MERS coronavirus MERS: emergence of a novel human coronavirus Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV)-worldwide Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques Middle East respiratory syndrome novel corona MERS-CoV infection.


id: cord-289090-7x2752j4
author: Vergison, Anne
title: Microbiology of otitis media: A moving target
date: 2008-12-23
extension: .txt
mime: text/plain
words: 3447
sentence: 131
flesch: 31
cache: cache/cord-289090-7x2752j4.txt
txt: txt/cord-289090-7x2752j4.txt
summary:
  It was recovered in middle ear fluid (MEF) in 12% of first AOM episodes compared with 25% of all subsequent OM episodes, and when only the first AOM episodes were considered, no peak in the incidence of H. influenzae AOM could be demonstrated in children over 1 year of age. Bacteriological and clinical observations Otitis media: a clinical and bacteriological correlation Association of clinical signs and symptoms with pneumococcal acute otitis media by serotype -implications for vaccine effect Acute otitis media: diagnosis and management in the year 2000 Complications of acute otitis media in children in southern Finland National differences in incidence of acute mastoiditis: relationship to prescribing patterns of antibiotics for acute otitis media? Acute mastoiditis in Southern Israel: a twelve year retrospective study Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database Pathogens causing recurrent and difficult-to-treat acute otitis media Evidence of bacterial metabolic activity in culture-negative otitis media with effusion Phenotypic characterization of Streptococcus pneumoniae biofilm development Role of sialic acid and complex carbohydrate biosynthesis in biofilm formation by nontypeable Haemophilus influenzae in the chinchilla middle ear Biofilm formation by nontypeable Haemophilus influenzae: strain variability, outer membrane antigen expression and role of pili Biofilm formation by Moraxella catarrhalis in vitro: roles of the UspA1 adhesin and the Hag hemagglutinin Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media The antibiotic paradox Outpatient antibiotic use in Europe and association with resistance: a cross-national database study Streptococcus pneumoniae: epidemiology and patterns of resistance European Academies Science Advisory Council.


id: cord-257792-m7nij17v
author: Ng, Oi-Wing
title: Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
date: 2016-04-12
extension: .txt
mime: text/plain
words: 4258
sentence: 147
flesch: 48
cache: cache/cord-257792-m7nij17v.txt
txt: txt/cord-257792-m7nij17v.txt
summary:
  Here, the identification of T cell responses against SARS-CoV structural S, N and M proteins at 9 and 11 years post-infection suggests the long-term persistence of these responses. Percentages of T cell responses represent that of CD4 + or CD8 + T cells over total T cell population after in vitro expansion in the presence of SARS peptide mixtures.


id: cord-310249-cvv77f10
author: Yule, Terecita D.
date: 1997-05-31
extension: .txt
mime: text/plain
words: 4614
sentence: 184
flesch: 39
cache: cache/cord-310249-cvv77f10.txt
txt: txt/cord-310249-cvv77f10.txt
title:
  Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease

summary:
  Clinical scores significantly correlated (PcO.05) with both a-1AG (r=0.54) and SAA (rz0.78) on day 5 and similarly on day 7. Using cell specific antibodies and flow cytometric analysis, a mean of 88% of leukocytes in peripheral Days Post CPV-2 Challenge blood were positively identified as T-cells (CD4+ and CD@, pan-T), B-cells, monocytes, and neutrophils when compared to the absolute leukocyte count obtained conventionally. To visualize virus infected cells, the monolayers were fixed with 80% acetone, then reacted with a monoclonal antibody (mab) (1:lOOOO) specific for the major capsid protein (VPl), followed by fluorescein conjugated anti-murine IgG (Kierkegaard and Perry International, Gaithersburg, MD).


id: cord-255549-i2o6rs29
author: Pagliusi, Sonia
title: Vaccines: Shaping global health()
date: 2017-03-14
extension: .txt
mime: text/plain
words: 4361
sentence: 234
flesch: 37
cache: cache/cord-255549-i2o6rs29.txt
txt: txt/cord-255549-i2o6rs29.txt
summary:
  M-P. Kieny reviewed evolving collaborative innovation in vaccine development. Access to funding for vaccine development is also getting increasingly difficult as it takes about 6 years for a vaccine to reach the market, and most investors prefer faster and higher returns.


id: cord-279364-j93f6eso
author: Liao, Qiuyan
date: 2020-05-07
extension: .txt
mime: text/plain
words: 4841
sentence: 178
flesch: 28
cache: cache/cord-279364-j93f6eso.txt
txt: txt/cord-279364-j93f6eso.txt
title:
  What influenza vaccination programmes are preferred by healthcare personnel? A discrete choice experiment

summary:
  Influenza vaccination coverage and effectiveness Seasonal influenza vaccination in Australian hospital health care workers: a review Testing an integrative theory of health behavioural change for predicting seasonal influenza vaccination uptake among healthcare workers. Several studies have used DCE to examine factors that determine preference for influenza vaccination [29]


id: cord-299952-xvtt8fz8
author: Gao, LuLu
date: 2010-06-17
extension: .txt
mime: text/plain
words: 4448
sentence: 180
flesch: 45
cache: cache/cord-299952-xvtt8fz8.txt
txt: txt/cord-299952-xvtt8fz8.txt
title:
  A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits

summary:
  The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers Prevention of experimental coronavirus colds with intranasal alpha-2b interferon Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a Could preventive intranasal interferon lower the morbidity in children prone to respiratory illness? Though most of viral respiratory infections usually represent mild, selflimited clinical manifestations, they are leading causes of morbidity in certain groups or populations (e.g., children, military population) and remain a heavy burden of disease


id: cord-252856-oc0zd11h
author: Pagliusi, Sonia
date: 2016-06-30
extension: .txt
mime: text/plain
words: 4471
sentence: 197
flesch: 37
cache: cache/cord-252856-oc0zd11h.txt
txt: txt/cord-252856-oc0zd11h.txt
title:
  Quality vaccines for all people(): Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05–07th October 2015, Bangkok, Thailand

summary:
  Prevention of shortages starts at country level, while PAHO acts regionally to facilitate timely and sufficient supply, and vaccine manufacturers worldwide are essential for assured global supply. The DCVMN 2015 Annual General Meeting gave rich insights into advances in vaccine technologies and development of new vaccines, and provided valuable opportunity for vaccine manufacturers, regulatory authorities and international organisations to have face-to-face interactions.


id: cord-269448-1jikrn37
author: Borja-Cabrera, G.P.
title: Immunogenicity assay of the Leishmune(®) vaccine against canine visceral leishmaniasis in Brazil
date: 2008-09-15
extension: .txt
mime: text/plain
words: 4949
sentence: 188
flesch: 40
cache: cache/cord-269448-1jikrn37.txt
txt: txt/cord-269448-1jikrn37.txt
summary:
  Recently we described the safety analysis of Leishmune ® vaccine performed in a cohort of 600 dogs from Brazilian endemic and epidemic areas of canine and human visceral leishmaniasis. In the present investigation we report the immunogenicity assay of Leishmune ® , monitored in the same dog cohort, confirming the immuno protective potential previously described for the FML-saponin vaccine [17, 18] and disclosing the potential use of Leishmune ® vaccine to interrupt epidemics.


id: cord-282764-d9x1wii6
author: Chang, Chia-Yin
date: 2006-02-20
extension: .txt
mime: text/plain
words: 4832
sentence: 164
flesch: 44
cache: cache/cord-282764-d9x1wii6.txt
txt: txt/cord-282764-d9x1wii6.txt
title:
  Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development

summary:
  Therefore, several different strategies for improving S TR2 protein expression in mammalian cells were investigated in this report, including intron addition and the application of exon splicing enhancers. As the intron and its splicing out was known to enhance each step of RNA metabolism, including transcription, poly(A) tail addition, mRNA exportation, translation, and translated protein stability [12] , hence we first studied the intron-enhancing effect on S TR2 protein expression.


id: cord-293234-ouykx6g5
author: Puig-Barberà, J.
date: 2012-08-24
extension: .txt
mime: text/plain
words: 4424
sentence: 179
flesch: 38
cache: cache/cord-293234-ouykx6g5.txt
txt: txt/cord-293234-ouykx6g5.txt
title:
  Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A case–case comparison, case-control study

summary:
  As a consequence of antigenic drift, influenza vaccines are to be a produced every year [3] . Information related to the administration of the 2009-2010 seasonal influenza vaccine, the A(H1N1) pandemic vaccine and previous 23-valent polysaccharide plain pneumococcal vaccinations was obtained from the Vaccine Information System.


id: cord-285128-48l1w65p
author: Custers, Jerome
date: 2020-10-03
extension: .txt
mime: text/plain
words: 4758
sentence: 182
flesch: 29
cache: cache/cord-285128-48l1w65p.txt
txt: txt/cord-285128-48l1w65p.txt
title:
  Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment

summary:
  In the unlikely event that recombination occurs between vaccine vector and wild-type adenoviruses, the virulence can maximally be 22 equal to the wild-type adenovirus already present in the tissue. The vector genome (linear ds-DNA) travels to the nucleus of the host cell where antigen expression occurs, in the absence of vaccine vector replication.


id: cord-010266-elhgew3x
author: Spier, R.E.
title: Ethical aspects of vaccines and vaccination
date: 1998-12-02
extension: .txt
mime: text/plain
words: 5155
sentence: 178
flesch: 44
cache: cache/cord-010266-elhgew3x.txt
txt: txt/cord-010266-elhgew3x.txt
summary:
  key: cord-010266-elhgew3x authors: Spier, R.E. title: Ethical aspects of vaccines and vaccination date: 1998-12-02 journal: Vaccine DOI: 10.1016/s0264-410x(98)00169-8 sha: doc_id: 10266 cord_uid: elhgew3x nan Published by Elsevier Science Ltd. An example of the implications of these changes may be seen in the area of vaccines and vaccination which evinces the pressing need to review traditional ethical positions to take the maximum advantage of the potential for animal and human benefit inherent in this prophylactic approach to healthcare.


id: cord-274110-nyyunoha
author: Orlinger, Klaus K.
title: An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system
date: 2010-04-26
extension: .txt
mime: text/plain
words: 5129
sentence: 202
flesch: 44
cache: cache/cord-274110-nyyunoha.txt
txt: txt/cord-274110-nyyunoha.txt
summary:
  West Nile and dengue viruses Flaviviridae: the viruses and their replication Functional cDNA clones of the Flaviviridae: strategies and applications A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication Infectious cDNA clones of Langat tick-borne flavivirus that differ from their parent in peripheral neurovirulence Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA Characterization of infectious Murray Valley encephalitis virus derived from a stably cloned genome-length cDNA Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain) Completion of Kunjin virus RNA sequence and recovery of an infectious RNA transcribed from stably cloned full-length cDNA Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53 Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication Infectious cDNA clones of tick-borne encephalitis virus European subtype prototypic strain Neudoerfl and high virulence strain Hypr Infectious clone construction of dengue virus type 2, strain Jamaican 1409, and characterization of a conditional E6 mutation Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3 deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice Infectious RNA transcripts from fulllength dengue virus type 2 cDNA clones made in yeast Construction of a full length infectious clone for dengue-1 virus Western Pacific, 74 strain Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation Infectious cDNA clone of the epidemic west nile virus from New York City Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates An infectious clone of the West Nile flavivirus A new strategy in design of +RNA virus infectious clones enabling their stable propagation in E. coli Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template Synthetic viruses: a new opportunity to understand and prevent viral disease Functional analysis of the tick-borne encephalitis virus cyclization elements indicates major differences between mosquito-borne and tick-borne flaviviruses Proteolytic activation of tick-borne encephalitis virus by furin Kunjin virus replicons: an RNAbased, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses The test-tube synthesis of a chemical called poliovirus Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides Characterization of the reconstructed 1918 Spanish influenza pandemic virus Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice Rates of spontaneous mutation Viral quasispecies Addressing biosecurity concerns related to the synthesis of select agents. RNA viruses replicate their genome with an error prone mechanism (for reviews see [33] ), resulting in a multitude of distinct but related nucleic acids forming a quasispecies [34] .


id: cord-255734-038xu4hq
author: Taylor, Deborah R.
title: Obstacles and advances in SARS vaccine development
date: 2006-02-13
extension: .txt
mime: text/plain
words: 5338
sentence: 244
flesch: 42
cache: cache/cord-255734-038xu4hq.txt
txt: txt/cord-255734-038xu4hq.txt
summary:
  A novel coronavirus associated with severe acute respiratory syndrome SARS-beginning to understand a new virus Severe acute respiratory syndrome coronavirus phylogeny: toward consensus Identification of a new human coronavirus Coronaviridae: the viruses and their replication Lung pathology of fatal severe acute respiratory syndrome SARS coronavirus-infected cells in lung detected by new in situ hybridization technique Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome SARS-related virus predating SARS outbreak Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors SARS in newborns and children Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China Role of China in the quest to define and control severe acute respiratory syndrome Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice Mice susceptible to SARS coronavirus Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Mechanisms of host defense following severe acute respiratory syndromecoronavirus (SARS-CoV) pulmonary infection of mice Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1 Virology: SARS virus infection of cats and ferrets Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS Koch's postulates fulfilled for SARS virus Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Macaque model for severe acute respiratory syndrome Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Protection of chickens after live and inactivated virus vaccination against challenge with nephropathologenic infectious bronchitis virus Safety and efficacy of a modified-live canine coronavirus vaccine in dogs Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees Live attenuated varicella vaccine Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression Genetically engineered vaccines: an overview Developing new smallpox vaccines Current status and future trends in vaccine regulation-USA SARS-associated coronavirus quasispecies in individual patients SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting Mosaic evolution of the severe acute respiratory syndrome coronavirus Antibody-dependent enhancement of virus infection and disease The role of IgG subclass of mouse monoclonal antibodies in antibody-dependent enhancement of feline infectious peritonitis virus infection of feline macrophages Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus Identification of an antigenie determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV Subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain Assembly of human severe acute respiratory syndrome coronavirus-like particles Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Effects of a SARS-associated coronavirus vaccine in monkeys Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine DNA vaccine of SARS-CoV S gene induces antibody response in mice A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation Kanta Subbarao, Edward Tabor, Miriam Darnell, Robin Levis and Hira Nakhasi are gratefully acknowledged for comments on the manuscript. [12] noted that a rapid decline of T-cell subsets in the periphery was observed in patients during the acute phase of SARS infection, but they observed restoration of T cells during recovery.


id: cord-254620-xcblqg4z
author: Harmon, Shawn H.E.
title: Immunization governance: Mandatory immunization in 28 Global NITAG Network countries()
date: 2020-09-26
extension: .txt
mime: text/plain
words: 5814
sentence: 259
flesch: 38
cache: cache/cord-254620-xcblqg4z.txt
txt: txt/cord-254620-xcblqg4z.txt
summary:
  key: cord-254620-xcblqg4z authors: Harmon, Shawn H.E.; Faour, David E.; MacDonald, Noni E.; Graham, Janice E.; Steffen, Christoph; Henaff, Louise; Shendale, Stephanie title: Immunization governance: Mandatory immunization in 28 Global NITAG Network countries() date: 2020-09-26 journal: Vaccine DOI: 10.1016/j.vaccine.2020.09.053 sha: doc_id: 254620 cord_uid: xcblqg4z International trends currently favour greater use of mandatory immunization. Mandatory immunization currently exists in only two Canadian provinces (Ontario and New Brunswick; previously, Manitoba also had mandatory immunization).


id: cord-263443-m98qisld
author: Goldman, Ran D.
title: Caregiver willingness to vaccinate their children against COVID-19: cross sectional survey
date: 2020-10-10
extension: .txt
mime: text/plain
words: 1034
sentence: 22
flesch: 6
cache: cache/cord-263443-m98qisld.txt
txt: txt/cord-263443-m98qisld.txt
summary:
  Int 400 Vaccine hesitancy: an overview Planning for a COVID-19 vaccination program Fauci says COVID-19 vaccine may not get US to herd immunity if too many people 406 refuse to get it Exploring Lessons Learned from a Century of Outbreaks: 410 Readiness for 2030 Factors associated with uptake of vaccination against 413 pandemic influenza: A systematic review Healthcare workers as parents: Prior history of pandemic vaccine coverage was as low as 40% among children in the United States during the 2009 H1N1 influenza pandemic.


id: cord-260334-xo8ruswo
author: New, R.R.C.
title: Antibody-mediated protection against MERS-CoV in the murine model()
date: 2019-07-09
extension: .txt
mime: text/plain
words: 5762
sentence: 193
flesch: 43
cache: cache/cord-260334-xo8ruswo.txt
txt: txt/cord-260334-xo8ruswo.txt
summary:
  Hospital outbreak of Middle East respiratory syndrome coronavirus Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans MERS-CoV origin and animal reservoir Novel betacoronavirus in dromedaries of the Middle East Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction Spiking the MERS-coronavirus receptor Crystal structure of the receptor-binding domain from newly emerged middle east respiratory syndrome coronavirus Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transduced mice from MERS-CoV infection Evaluation of candidate vaccine approaches for MERS-CoV Introduction of neutralising immunogenncity index to the rational design of MERS coronavirus sub-unit vaccines Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge MERS-CoV spike protein: targets for vaccines and therapeutics Toward developing a preventive MERS-CoV vaccine-report from a workshop organized by the Saudi Arabia ministry of health and the international vaccine institute Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity A new oil-based antigen delivery formulation for both oral and parenteral vaccination Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice Dual route vaccination for plague with emergency use applications Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans Severe respiratory illness caused by a novel coronavirus Rapid generation of a mouse model for Middle East respiratory syndrome Real-time reverse transcription-PCR assay panel for middle east respiratory syndrome coronavirus Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody.


id: cord-288309-6pw7t512
author: Kusters, J. G.
date: 1990-12-31
extension: .txt
mime: text/plain
words: 1973
sentence: 86
flesch: 57
cache: cache/cord-288309-6pw7t512.txt
txt: txt/cord-288309-6pw7t512.txt
title:
  Sequence evidence for RNA recombination in field isolates of avian coronavirus infectious bronchitis virus

summary:
  virus retaining spike glycopolypeptide S2 but not $1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection Eyidence for a coiled-coil structure in the spike protein of coronaviruses Coronavirus proteins: biogenesis of avian bronchitis virus virion proteins Phylogeny of antigenic variants of avian coronavirus IBV Occurrence and significance of infectious bronchitis virus variant strains in egg and broiler production in the Netherlands Comparison of the spike precursor sequences of coronavirus IBV strains M41 and 6•82 with that of IBV Beaudette Cloning and sequencing of genes encoding structural proteins of avian infectious bronchitis virus The peplomer protein sequence of the M41 strain of coronavirus IBV and its comparison with Beaudette strains A comprehensive sequence analysis program for the IBM personal computer Confidence limits on phylogenies: an approach using the bootstrap Highfrequency RNA recombination of murine coronaviruses In vivo RNA-RNA recombination of coronavirus in mouse brain Cloning and sequencing of the gene encoding the spike protein of coronavirus IBV Evolution of avian coronavirus IBV: sequence of the matrix glycoprotein gene and intergenic region of several serotypes The tree based on S1 gene sequences (I in Figure 2b ) has the same topology as an $2 tree based on region II in $2. KB8523 has shifted to the D1466 branch in a tree for region III of $2.


id: cord-277355-si3g5dih
author: He, Yu
title: The role of capsid in the flaviviral life cycle and perspectives for vaccine development
date: 2020-09-17
extension: .txt
mime: text/plain
words: 6906
sentence: 257
flesch: 40
cache: cache/cord-277355-si3g5dih.txt
txt: txt/cord-277355-si3g5dih.txt
summary:
  capsid protein Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with large deletions in protein C Solution structure of dengue virus capsid protein reveals another fold Dynamics of zika virus capsid protein in solution: the properties and exposure of the hydrophobic cleft are controlled by the alpha-helix 1 sequence West Nile virus core protein; tetramer structure and ribbon formation Crystal structure of the capsid protein from Zika virus Crystal structure of the Japanese encephalitis virus capsid protein Structural insight into the Zika virus capsid encapsulating the viral genome Dengue virus capsid protein usurps lipid droplets for viral particle formation Maintenance of dimer conformation by the dengue virus core protein alpha 4-alpha 4'= helix pair is critical for nucleocapsid formation and virus production Partial intrinsic disorder governs the dengue capsid protein conformational ensemble Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence Mimicking live flavivirus immunization with a noninfectious RNA vaccine Functional requirements of the yellow fever virus capsid protein Helices alpha 2 and alpha 3 of west Nile virus capsid protein are dispensable for assembly of infectious virions NS2B-3 proteinasemediated processing in the yellow fever virus structural region: in vitro and in vivo studies Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes A flavivirus signal peptide balances the catalytic activity of two proteases and thereby facilitates virus morphogenesis Role of capsid anchor in the morphogenesis of Zika virus Increased expression of capsid protein in trans enhances production of singleround infectious particles by West Nile virus DNA vaccine candidate Production and characterization of vaccines based on flaviviruses defective in replication A single-dose live-attenuated Zika virus vaccine with controlled infection rounds that protects against vertical transmission e485 DENV2 Pseudoviral Particles with Unprocessed Capsid Protein Are Assembled and Infectious Viral RNA switch mediates the dynamic control of flavivirus replicase recruitment by genome cyclization Long-range RNA-RNA interactions circularize the dengue virus genome Essential role of cyclization sequences in flavivirus RNA replication The 5' and 3' downstream AUG region elements are required for mosquito-borne flavivirus RNA replication RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication The capsid-coding region hairpin element (cHP) is a critical determinant of dengue virus and West Nile virus RNA synthesis Novel cis-Acting element within the capsid-coding region enhances flavivirus viral-RNA replication by regulating genome cyclization In addition to having safety and efficiency similar to those of SRIPs, they are more suitable for meeting the challenges of rapid development and large-scale deployment for emerging virus vaccines [99] .


id: cord-253477-gptjqti7
author: Ball, Christopher
date: 2019-12-10
extension: .txt
mime: text/plain
words: 6872
sentence: 274
flesch: 51
cache: cache/cord-253477-gptjqti7.txt
txt: txt/cord-253477-gptjqti7.txt
title:
  Comparative protective immunity provided by live vaccines of Newcastle disease virus or avian metapneumovirus when co-administered alongside classical and variant strains of infectious bronchitis virus in day-old broiler chicks

summary:
  IBV vaccine strains were detected in Groups B1 (Mass vaccinated À 99% similarity) and C1 (793B vaccinated À 96% similarity). To further investigate this, the growth kinetics and genetic characteristics of live IBV vaccines used in this study were cross compared with previous reports [26, 64] .


id: cord-281635-a6ia8kxf
author: Bellinzoni, R. C.
date: 1989-06-30
extension: .txt
mime: text/plain
words: 3727
sentence: 131
flesch: 41
cache: cache/cord-281635-a6ia8kxf.txt
txt: txt/cord-281635-a6ia8kxf.txt
title:
  Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina

summary:
  Veterinaermed Passive immunity in calf rotavirus infections: Maternal vaccination increases and prolongs immunoglobulin G 1 antibody secretion in milk Evolution des anticorps anti-rota dans le lait de vaches traitees en fin de gestation soit par le vaccine anti-rota complet, soit par I'adjuvant seul Incidence of rotavirus in beef herds in Argentina Serotypic similarity and diversity of rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization Antigenic relationships among some bovine rotaviruses: serum neutralization and cross-protection in gnotobiotic calves Serotyping of cell culture adapted subgroup 2 human rotavirus strains by neutralization Bovine rotavirus serotypes and their significance for immunization Bovine milk immunogtobulins for passive immunity to infantile rotavirus gastroenteritis key: cord-281635-a6ia8kxf authors: Bellinzoni, R. C.; Blackhall, J.; Baro, N.; Auza, N.; Mattion, N.; Casaro, A.; La Torre, J. L.; Scodeller, E. A. title: Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina date: 1989-06-30 journal: Vaccine DOI: 10.1016/0264-410x(89)90241-7 sha: doc_id: 281635 cord_uid:


id: cord-276009-p98wjtjb
author: Iyer, Arun V.
date: 2009-02-05
extension: .txt
mime: text/plain
words: 7553
sentence: 304
flesch: 39
cache: cache/cord-276009-p98wjtjb.txt
txt: txt/cord-276009-p98wjtjb.txt
title:
  Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01

summary:
  A neurotropic virus isolated from the blood of a native of Uganda Flaviviridae: the viruses and their replication Structures of immature flavivirus particles Conformational changes of the flavivirus E glycoprotein Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States Possible West Nile virus transmission to an infant through breast-feeding-Michigan West Nile virus infection: a pediatric perspective Transfusion-associated transmission of West Nile virus-Arizona Investigations of West Nile virus infections in recipients of blood transfusions Detection of West Nile virus in blood donations-United States A fatal case of West Nile virus infection in a bone marrow transplant recipient Nile virus infection in organ donor and transplant recipients-Georgia and Florida Transmission of West Nile virus from an organ donor to four transplant recipients Possible dialysis-related west nile virus transmission-Georgia The West Nile Virus and the dialysis/transplant patient West Nile virus: pathogenesis and therapeutic options Skin manifestations of West Nile virus infection Characteristics of the rash associated with West Nile virus fever West Nile virus neuroinvasive disease West Nile virus infection: a new acute paralytic illness West Nile encephalitis presenting as a stroke Acute pancreatitis in West Nile fever The pathology of human West Nile virus infection West Nile virus encephalitis with myositis and orchitis West Nile virus (WNV) was first isolated more than 70 years ago from a febrile patient in the West Nile province of Uganda [1] .


id: cord-271153-c0aw6jkz
author: Privor-Dumm, Lois
title: Archetype analysis of older adult immunization decision-making and implementation in 34 countries
date: 2020-05-27
extension: .txt
mime: text/plain
words: 7748
sentence: 326
flesch: 41
cache: cache/cord-271153-c0aw6jkz.txt
txt: txt/cord-271153-c0aw6jkz.txt
summary:
  Many of the countries in this archetype lack a strong NITAG for adult vaccine decisions, but exhibit some elements of the ''disease prevention archetype. Understanding the different approaches countries have taken on adult immunization could help provide future learnings and technical support for adult vaccines within life-course immunization strategies.


id: cord-266204-ipa017wz
author: Poland, G. A.
title: Personalized vaccinology: A review
date: 2018-08-28
extension: .txt
mime: text/plain
words: 7241
sentence: 234
flesch: 27
cache: cache/cord-266204-ipa017wz.txt
txt: txt/cord-266204-ipa017wz.txt
summary:
  Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology Cytometry by time-offlight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8 + T cell phenotypes Highresolution myogenic lineage mapping by single-cell mass cytometry Metabolic phenotypes of response to vaccination in humans Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century Pharmacology, vaccinomics, and the second golden age of vaccinology A systems biology approach to the effect of aging, immunosenescence and vaccine response Genetics and vaccines in the era of personalized medicine The weight of obesity on the human immune response to vaccination Understanding immunosenescence to improve responses to vaccines Vaccine immunogenetics: bedside to bench to population Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology Vaccine discovery and translation of new vaccine technology Systems vaccinology: learning to compute the behavior of vaccine induced immunity Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection Role of HLA, KIR, MICA, and cytokines genes in leprosy Association of variants in BAT1-LTA-TNF-BTNL2 genes within 6p21.3 region show graded risk to leprosy in unrelated cohorts of Indian population Immunogenetics of HIV disease Vaccinomics provides the opportunity to examine not only immune response genes likely to be involved in vaccine response, but also the possibility of identifying the influence of new (uncharacterized) genes on vaccine-induced immunity.


id: cord-296469-h0ma163u
author: Gellin, Bruce G.
title: Preparing for the unpredictable: The continuing need for pandemic influenza preparedness
date: 2016-10-26
extension: .txt
mime: text/plain
words: 1502
sentence: 57
flesch: 39
cache: cache/cord-296469-h0ma163u.txt
txt: txt/cord-296469-h0ma163u.txt
summary:
  While this event is advertised as a programme review, in reality as an examination of the progress achieved during the decade, it should also serve to direct the global community on the path forward for the work that remains to achieve global pandemic influenza vaccine and vaccination preparedness. [14] , and WHO's restructuring of its approach to global health emergencies The Global Action Plan for Influenza Vaccines was structured around three broad objectives that underpin pandemic influenza vaccine and vaccination preparedness: -evidence-based increase in seasonal influenza vaccine use; -increase in influenza vaccine production capacity and regulatory capacity; -research and development for improved influenza vaccines.


id: cord-301601-4vkag60z
author: Nakayama, Tetsuo
title: Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens
date: 2016-01-04
extension: .txt
mime: text/plain
words: 2950
sentence: 123
flesch: 37
cache: cache/cord-301601-4vkag60z.txt
txt: txt/cord-301601-4vkag60z.txt
summary:
  Recombinant measles viruses expressing RSV M2-1 or NP (MVAIK/RSV/M2-1 and MVAIK/RSV/NP) were generated, together with MVAIK/RSV/F. No detectable neutralizing antibody against RSV was induced in cotton rats immunized with recombinant measles virus expressing M2-1 or NP, whereas high titers of neutralizing antibody were induced after immunization with those expressing F or G protein. When considering a clinical usage of recombinant measles vaccine candidates expressing RSV antigen in young infants, growth inhibition of vaccine virus was supposed because of maternally conferred immunity.


id: cord-307939-rydgncys
author: Wu, Shuangsheng
title: Willingness to accept a future influenza A(H7N9) vaccine in Beijing, China
date: 2018-01-25
extension: .txt
mime: text/plain
words: 3760
sentence: 146
flesch: 45
cache: cache/cord-307939-rydgncys.txt
txt: txt/cord-307939-rydgncys.txt
summary:
  However, previous studies have shown that residents' willingness of future H7N9 influenza vaccine uptake varied across different regions and sub-populations: 50.5% among the general population of Hong Kong, 84% among the employees of food production of Guangzhou and 42.2% among live poultry traders of Guangzhou, a city located in Southern China Among those who had heard of H7N9, 59.5% of the general adult population would be willing to accept a future H7N9 vaccine, and approximately half of them reported ‘I am afraid of being infected by H7N9’ and ‘H7N9 vaccine can prevent infections’, and 28.1% reported ‘my daily life is affected by H7N9’.


id: cord-276209-5999g9gp
author: Poland, Gregory A.
title: Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development
date: 2020-06-02
extension: .txt
mime: text/plain
words: 1609
sentence: 77
flesch: 49
cache: cache/cord-276209-5999g9gp.txt
txt: txt/cord-276209-5999g9gp.txt
summary:
  What does history teach us in regard to vaccine development? In vaccine development, we need only look back a handful of decades to recall failed vaccines against measles and RSV that used inactivated virus approaches.


id: cord-294856-eeh2a0t8
author: Lambert, Paul-Henri
date: 2020-05-25
extension: .txt
mime: text/plain
words: 5249
sentence: 179
flesch: 32
cache: cache/cord-294856-eeh2a0t8.txt
txt: txt/cord-294856-eeh2a0t8.txt
title:
  Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines

summary:
  Virology Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates Immunogenicity and protective efficacy in monkeys of purified inactivated Verocell SARS vaccine. In murine models, evidence for vaccine related disease enhancement has been demonstrated for inactivated whole vaccine (with and without alum), vectored vaccine expressing N protein (but not seen with vectored vaccine expressing S protein in same report), a replicon particle platform expressing S protein, and a vectored vaccine expressing S proteins.


id: cord-288938-4bheqtk5
author: Hönemann, M.
date: 2019-10-08
extension: .txt
mime: text/plain
words: 3202
sentence: 161
flesch: 49
cache: cache/cord-288938-4bheqtk5.txt
txt: txt/cord-288938-4bheqtk5.txt
title:
  Influenza B virus infections in Western Saxony, Germany in three consecutive seasons between 2015 and 2018: Analysis of molecular and clinical features

summary:
  Last accessed 15.12 Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine Seasonal Influenza Reports The quadrivalent approach to influenza vaccination Evolutionary dynamic of antigenic residues on influenza B hemagglutinin Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination Three types of broadly reacting antibodies against Influenza B viruses induced by vaccination with seasonal influenza viruses Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity Prediction of influenza B vaccine effectiveness from sequence data Intra-season Waning of Influenza vaccine effectiveness Simultaneous detection of influenza viruses A and B using real-time quantitative PCR WHO information for the molecular detection of influenza viruses Effect of a single mutation in neuraminidase on the properties of Influenza B virus isolates MEGA6: molecular evolutionary genetics analysis version 6.0 Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries Estimation of influenza-attributable medically attended acute respiratory illness by influenza type/subtype and age Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: A Danish Nationwide Cohort Study Estimating influenza disease burden from population-based surveillance data in the United States Age-and sexrelated risk factors for influenza-associated mortality in the United States between 1997-2007 Circulating pattern and genomic characteristics of influenza B viruses in Taiwan from 2003 to 2014 Human monoclonal antibodies broadly neutralizing against influenza B virus Cross-lineage protection by human antibodies binding the influenza B hemagglutinin Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine From original antigenic sin to the universal influenza virus vaccine Immune history profoundly affects broadly protective B cell responses to influenza Age, influenza pandemics and disease dynamics This research was partially supported by the Association of Sponsors and Friends of Leipzig University (Vereinigung von Förderern und Freunden der Universität Leipzig). First isolated in 1940, influenza B virus diverged into two lineages, Victoria and Yamagata, in the late 1970s with similar clinical [2] but different phylodynamic properties [3] .


id: cord-283475-28900qlr
author: Yu, Wenzhou
title: Vaccine-preventable disease control in the People’s Republic of China: 1949–2016
date: 2018-12-18
extension: .txt
mime: text/plain
words: 5048
sentence: 184
flesch: 38
cache: cache/cord-283475-28900qlr.txt
txt: txt/cord-283475-28900qlr.txt
summary:
  China's experience with hepatitis B vaccine is an interesting case study on use of cost-sharing to finance the introduction of new vaccines that may be of relevance to middle-income countries ineligible for GAVI support. Farm collectives and the RCMS were dismantled, and while EPI vaccines were still provided for free, funding for vaccine delivery switched to fee-for-service, usually 1-2 RMB paid by parents to the village or township doctor for each dose administered.


id: cord-284882-8vil7k5l
author: MacDonald, Angus J.
date: 2005-05-16
extension: .txt
mime: text/plain
words: 3944
sentence: 148
flesch: 48
cache: cache/cord-284882-8vil7k5l.txt
txt: txt/cord-284882-8vil7k5l.txt
title:
  rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens

summary:
  Since these effects occurred in vaccinated mice in the absence of adjuvant, we asked the question whether the protein could act as an adjuvant to assist unrelated proteins in inducing antibody responses. In Fig. 1 , the uppermost lines show that the treated recombinant protein (rOv-ASP-1A) performed better than the untreated protein in augmenting antibody responses to OVA in immunized mice.


id: cord-299323-riotkgj4
author: Seo, Yurim
date: 2020-10-13
extension: .txt
mime: text/plain
words: 3652
sentence: 166
flesch: 43
cache: cache/cord-299323-riotkgj4.txt
txt: txt/cord-299323-riotkgj4.txt
title:
  Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)

summary:
  This study compared vaccine prescribing information and patient information leaflet languages between FDA/Centers for Disease Control and Prevention (CDC) and EMA. Harmonized vaccine approval and administration would be valuable for diseases that impact the global community, as it would lead to faster access to potentially beneficial vaccines.


id: cord-276907-b855tj7x
author: Giersing, Birgitte K.
date: 2019-11-28
extension: .txt
mime: text/plain
words: 12257
sentence: 409
flesch: 33
cache: cache/cord-276907-b855tj7x.txt
txt: txt/cord-276907-b855tj7x.txt
title:
  Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016

summary:
  Dr. Jean-Marie Okwo-Bele, director of IVB, opened proceedings with a synopsis of the significant milestones in vaccine development in the nine months since the previous meeting in September 2015: the first dengue and malaria vaccines have been licensed or achieved the equivalent of licensure, respectively, the first RSV vaccine candidate has entered phase III studies in the elderly and pregnant women, the most advanced HIV vaccine candidate has met its endpoints in the interim analysis of a phase II study, and preparations to commence an efficacy study are underway, WHO convened the MERS-Coronavirus R&D community, and a phase I clinical study is now underway (NCT02670187), Ebola virus vaccines are under review and have progressed to the point of consideration for licensure in record time, There are co-ordinated efforts to develop a Zika virus vaccine as expeditiously as possible. In addition to these significant advances in vaccine development, the UK government published in May 2016 the report on 'Tackling Drug-Resistant Infections Globally' that it commissioned in collaboration with the Welcome Trust [2] .


id: cord-285613-hbd44euq
author: Søborg, Christian
title: Vaccines in a hurry
date: 2009-05-26
extension: .txt
mime: text/plain
words: 3805
sentence: 138
flesch: 39
cache: cache/cord-285613-hbd44euq.txt
txt: txt/cord-285613-hbd44euq.txt
summary:
  In the present discussion paper, we propose mechanisms to facilitate development of emergency vaccines in Europe by focusing on public–private scientific partnerships, fast-track approval of emergency vaccine by regulatory agencies and proposing incentives for emergency vaccine production in private vaccine companies. In the present discussion paper, we address mechanisms to facilitate development of emergency vaccines in Europe by focusing on regulatory aspects and proposing incentives for emergency vaccine production in private vaccine companies.


id: cord-267712-mhx8e5y0
author: Fang, Xinkui
title: Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors
date: 2012-02-08
extension: .txt
mime: text/plain
words: 5838
sentence: 230
flesch: 51
cache: cache/cord-267712-mhx8e5y0.txt
txt: txt/cord-267712-mhx8e5y0.txt
summary:
  In short, confluent BHK21 cells were infected with VSV M51, VSV G 28 or VSV M51-G 28 at a multiplicity of infection (MOI) of 1. In VSV M51 infected cells, IFN-␤ concentrations reached ∼2000 pg/mL, but the highest replication titer was ∼2 orders of magnitude lower than for VSV XN2 .


id: cord-309999-izdl0f2i
author: Qin, Ede
title: Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
date: 2006-02-13
extension: .txt
mime: text/plain
words: 3947
sentence: 176
flesch: 43
cache: cache/cord-309999-izdl0f2i.txt
txt: txt/cord-309999-izdl0f2i.txt
summary:
  The purity of SARS vaccine was 97.6% by HPLC identification and reacted with convalescent sera of SARS patients. HPLC analysis showed that the purity of SARS vaccine was 97.6%.


id: cord-316295-x636ux34
author: Roth, Bernhard
date: 2012-01-11
extension: .txt
mime: text/plain
words: 4143
sentence: 154
flesch: 39
cache: cache/cord-316295-x636ux34.txt
txt: txt/cord-316295-x636ux34.txt
title:
  Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses

summary:
  Collaborative studies have been initiated to investigate the growth and yield of influenza viruses in different cell lines, the efficiency and fidelity of influenza virus isolation, and the suitability for vaccine manufacture of different cell substrates key: cord-316295-x636ux34 authors: Roth, Bernhard; Mohr, Hannah; Enders, Martin; Garten, Wolfgang; Gregersen, Jens-Peter title: Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses date: 2012-01-11 journal: Vaccine DOI: 10.1016/j.vaccine.2011.11.063 sha: doc_id: 316295 cord_uid: x636ux34


id: cord-262542-vevsgkp6
author: Alharbi, Naif Khalaf
date: 2017-06-27
extension: .txt
mime: text/plain
words: 4957
sentence: 203
flesch: 45
cache: cache/cord-262542-vevsgkp6.txt
txt: txt/cord-262542-vevsgkp6.txt
title:
  ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

summary:
  All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. For MVA MERS vaccines chicken embryo fibroblast cells (CEFs) were infected with MVA parental virus that encodes dsRed marker instead of the native F11L ORF and transfected with MVA shuttle plasmids containing MERS-CoV spike gene (explained above) to allow recombination with the MVA genome and deletion of dsRed marker whilst keeping the F11 promoter sequence.


id: cord-317347-by8albr9
author: van Ginkel, Frederik W.
title: Age-dependent immune responses and immune protection after avian coronavirus vaccination
date: 2015-05-28
extension: .txt
mime: text/plain
words: 5815
sentence: 244
flesch: 50
cache: cache/cord-317347-by8albr9.txt
txt: txt/cord-317347-by8albr9.txt
summary:
  These data strongly support IBV vaccination after day 7 post hatch. To determine whether age of IBV vaccination affected the humoral immune response, plasma samples were collected 14 and 21 days and tears 14 days after vaccination with 3 × 10 5 EID 50 of a live-attenuated ArkDPI IBV vaccine strain on 1, 7 14, 21 or 28 days of age.


id: cord-282314-9cua2jzg
author: Albanese, Grace A.
date: 2018-10-01
extension: .txt
mime: text/plain
words: 6383
sentence: 269
flesch: 46
cache: cache/cord-282314-9cua2jzg.txt
txt: txt/cord-282314-9cua2jzg.txt
title:
  Biological and molecular characterization of ArkGA: A novel Arkansas serotype vaccine that is highly attenuated, efficacious, and protective against homologous challenge

summary:
  In P60, SNPs were seen in S1 as well as S2 of the Table 2 S1 amino acid sequence comparison of ArkGA vaccine virus and viral RNA isolated from 5 choanal cleft palate swabs on days 7, 10, and 14 post-vaccination. However, it has been shown that the ArkDPI vaccine has an atypical vaccine coverage and replication pattern when mass applied by spray, and previous data from our laboratory suggests that the percentage of chicks infected with vaccine virus by 10 days post-vaccination only reaches 15-25%


id: cord-273065-peqz7okh
author: Girard, Marc
title: Arboviruses: A global public health threat
date: 2020-04-24
extension: .txt
mime: text/plain
words: 5575
sentence: 212
flesch: 45
cache: cache/cord-273065-peqz7okh.txt
txt: txt/cord-273065-peqz7okh.txt
summary:
  Nevertheless, the substantial public health benefits of even a moderately effective dengue vaccine continue to drive all the efforts at developing dengue vaccines [29, 30] , hoping that safety concerns may be adequately addressed. Dr Joao Bosco Siqueira reported that Brazil had suffered from a shortage of yellow fever vaccine.


id: cord-302265-97sxlkjp
author: Ramasamy, R.
title: Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations
date: 2006-05-01
extension: .txt
mime: text/plain
words: 5453
sentence: 225
flesch: 44
cache: cache/cord-302265-97sxlkjp.txt
txt: txt/cord-302265-97sxlkjp.txt
summary:
  Exponentially growing L. lactis cells were induced for 4 h with a supernatant containing nisin A and the cells were pelleted by centrifugation, washed once in distilled water and resuspended in buffer (20% sucrose, 10 mM Tris-HCl pH8.1, 10 mM EDTA and 50 mM NaCl) containing 500 g ml −1 lysosyme and 15 units ml −1 mutanolysin (Sigma, USA) and heated to 55 • C for 15 min. Then 1 volume of 2× concentrated Laemmli sample buffer was added and the sample was heated to 100 • C for 3 min. MSA2-nCov, non-covalently bound to L. lactis GEM particles, was extracted from GEMs with sample buffer at 100 • C. Ten microlitres of aliquots (5 × 10 8 cells) were analysed by SDS-PAGE (12% NuPage gels with MOPS buffer; Invitrogen, USA) and stained with Coomassie R250(G) stain. For this purpose, L. lactis cells are pre-treated with an acid that removes surface components [15] , leaving non-living particles that we termed Gram-positive enhancer matrix (GEM)


id: cord-258902-h0wrs01h
author: Liu, Xianglei
date: 2020-09-22
extension: .txt
mime: text/plain
words: 5032
sentence: 187
flesch: 44
cache: cache/cord-258902-h0wrs01h.txt
txt: txt/cord-258902-h0wrs01h.txt
title:
  Enhanced Elicitation of Potent Neutralizing Antibodies by the SARS-CoV-2 Spike Receptor Binding Domain Fc Fusion Protein in Mice

summary:
  The impact of his tag on the detection of RBD binding titer is marginal ( Figure. S2C) . Four groups of 8-10 week old female BALB/c mice (n=5) were immunized twice (day 0 and day 14) subcutaneously with RBD proteins (10 μg/mouse) with or without adjuvant MF59.


id: cord-295850-nb6miso7
author: Zhang, Chuan-hai
date: 2005-05-02
extension: .txt
mime: text/plain
words: 2937
sentence: 122
flesch: 49
cache: cache/cord-295850-nb6miso7.txt
txt: txt/cord-295850-nb6miso7.txt
title:
  Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain

summary:
  Based on the potent antigenicity and immunogenicity, SARS-CoV S (spike, 139 kDa), N (nucleocapsid, 46 kDa) and M (membrane, 25 kDa) proteins may be selected as targets for SARS vaccine development [5] [6] . SARS coronavirus (SARS-CoV) is novel, mutative and highly infectious compared to other known coronaviruses.


id: cord-290783-ipoelk4h
author: Crouch, C. F.
date: 1985-09-30
extension: .txt
mime: text/plain
words: 4553
sentence: 142
flesch: 25
cache: cache/cord-290783-ipoelk4h.txt
txt: txt/cord-290783-ipoelk4h.txt
title:
  Vaccination against enteric rota and coronaviruses in cattle and pigs: Enhancement of lactogenic immunity

summary:
  A review Studies on rotaviral antibody in bovine serum and lacteal secretions using radioimmunoassay The rotaviruses Radioimmunological (RIA) and enzymimmunological (ELISA) detection of coronavirus antibodies in bovine serum and lacteal secretions Vaccination of cows with a combined rotavirus/ enterotoxigenic Escherichia coil K99 vaccine to protect newborn calves against diarrhoea Immune responses of pregnant cows to bovine rotavirus =mmunization Passive immunity in calf rotavirus infections. An analysis of Scourvax-Reo The efficacy of a modified live reo-like virus vaccine and an Escherichia coli bacterin for prevention of acute undifferentiated neonatal diarrhoea of beef calves Rotavirus infections in calves: Efficacy of oral vaccination in endemically infected herds Colostral and milk antibody titres in cows vaccinated with a modified live rotaviruscoronavirus vaccine L Passive immunity in calf diarrhoea: Vaccination with K99 antigen of enterotoxigenic Escherichia coli and rotavirus Passive immunity in calf rotavirus infections: Maternal vaccination increases and prolongs immunoglobulin G 1 antibody secretion in milk Evolution des anticorps anti rota dans le lait de vaches traitees en fin de Gestation soit par le vaccine ant=-rota complet, soit par I'adjuvant seul Passive protection of newborn calves against rotavirus by vaccination of their dams Die Wirksamkeitsprufung eimer inaktiv=erten rotavirus-vakzine in einem Milchviehbestand Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized or non-immunized cows Rotavirus infection in lambs: Studies on passive protection Development of passive immunity to porcine rotavirus in pigs protected from disease by bovine colostrum Diarrhoea in dairy calves reduced by feeding colostrum from cows vaccinated with rotavirus.


id: cord-263862-zzys31e9
author: Ryan, Elizabeth J.
date: 2007-04-30
extension: .txt
mime: text/plain
words: 5851
sentence: 237
flesch: 50
cache: cache/cord-263862-zzys31e9.txt
txt: txt/cord-263862-zzys31e9.txt
title:
  The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by Natural Killer (NK) cells enhancing Th1 polarization

summary:
  A low and transient amount of IFN-␣ could be detected at 2 h in the serum of ALVAC immunised mice (Fig. 2B) . Immuno-depletion of NK cells prior to ALVAC immunisation abrogated IFN-γ production indicating that they are the main cellular source of early IFN-γ in vivo.


id: cord-253656-2x4y403o
author: Ren, Wenlin
date: 2020-06-24
extension: .txt
mime: text/plain
words: 3699
sentence: 160
flesch: 56
cache: cache/cord-253656-2x4y403o.txt
txt: txt/cord-253656-2x4y403o.txt
title:
  Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates

summary:
  On day 27, the bleeds were collected for examination of anti-S1 antibody titers. As shown in Fig. 3A , all five mice developed strong anti-S1 IgG antibody titers (64,000 to 256,000).


id: cord-268369-yj7m0n0f
author: Wang, Keyang
date: 2006-03-15
extension: .txt
mime: text/plain
words: 5707
sentence: 236
flesch: 47
cache: cache/cord-268369-yj7m0n0f.txt
txt: txt/cord-268369-yj7m0n0f.txt
title:
  Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine

summary:
  For pandemic preparedness, developing and stockpiling rHA influenza vaccines against the present H5N1 strain may be a good option to provide some protection for the first response personnel and the population in the hard-hit areas in the case of a pandemic, and to win the precious time for manufacturing of a more specific influenza vaccine. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control Serious morbidity and mortality associated with influenza epidemics Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza Confronting the avian influenza threat: vaccine development for a potential pandemic Probable person-to-person transmission of avian influenza A (H5N1) Cell-based protein vaccines for influenza The role of cell culture vaccines in the control of the next influenza pandemic Next generation flu vaccine boosted by Chiron debacle Preparing for the next pandemic Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culturebased influenza vaccine A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line Webster RG. Moreover, two distantly related H1N1 rHA influenza vaccines using the baculovirusinsect cell expression system have also been demonstrated to partially protect mice against the lethal challenge of a recombinant 1918 pandemic influenza virus [24] .


id: cord-292528-8kdhf123
author: Lau, Yuk-Fai
date: 2009-02-25
extension: .txt
mime: text/plain
words: 6915
sentence: 285
flesch: 46
cache: cache/cord-292528-8kdhf123.txt
txt: txt/cord-292528-8kdhf123.txt
title:
  A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic

summary:
  There is an accumulating body of data showing that H5N1 virus vaccines are generally poorly immunogenic. The 2006-2007 South Hemisphere seasonal influenza vaccine, Fluvax, was from CSL Ptd Ltd. (Victoria, Australia).


id: cord-282158-08u3x1z4
author: Yang, William H.
date: 2013-09-13
extension: .txt
mime: text/plain
words: 5330
sentence: 189
flesch: 42
cache: cache/cord-282158-08u3x1z4.txt
txt: txt/cord-282158-08u3x1z4.txt
title:
  Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()

summary:
  The World Health Organization (WHO) encouraged the development and use of adjuvanted influenza A(H1N1)pdm09 vaccines [9, 10] , with the aim of dose-reduction, antigen-sparing and to potentially provide broader vaccine efficacy against drifted strains through cross-reactive immunity [11] . Based on the experience of developing a pre-pandemic A/H5N1 influenza vaccine utilizing AS03 (an ␣-tocopherol oil-in-water emulsion based Adjuvant System)


id: cord-275337-c3qr15es
author: Wright, Edward
date: 2009-11-27
extension: .txt
mime: text/plain
words: 5858
sentence: 227
flesch: 47
cache: cache/cord-275337-c3qr15es.txt
txt: txt/cord-275337-c3qr15es.txt
title:
  A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa

summary:
  Any dogs with VNAb levels that attained an IC 100 at a dilution of greater than or equal to 1:40 (by pseudotype assay) or a titre of 0.5 IU/ml (by FAVN assay) were considered positive (also referred to as adequate in this study). There were no discrepant results achieved using the FAVN or pseudotype assays and samples from the second visit.


id: cord-281676-yy5etfek
author: Dwivedi, Varun
date: 2011-05-23
extension: .txt
mime: text/plain
words: 5970
sentence: 206
flesch: 38
cache: cache/cord-281676-yy5etfek.txt
txt: txt/cord-281676-yy5etfek.txt
title:
  Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant

summary:
  Nasopharyngeal MALT contains the entire repertoire of immune cells which are strategically located to orchestrate regional immune functions against airborne infections [11] . Consistent with the reduced lung lesions and viremia, a significantly increased frequency of IFN-␥- Table 1 Frequency of immune cells in pigs inoculated intranasally with mock (no vaccination and no challenge), unvaccinated (n = 9) or vaccinated with PRRS-MLV+ Mtb WCL (n = 9) and then challenged with PRRSV MN184.


id: cord-275635-d50bxe7c
author: Yuan, Xiaomin
date: 2015-07-31
extension: .txt
mime: text/plain
words: 3999
sentence: 164
flesch: 49
cache: cache/cord-275635-d50bxe7c.txt
txt: txt/cord-275635-d50bxe7c.txt
title:
  Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein

summary:
  Domains in the peplomer glycoprotein Bacterial expression of antigenic sites A and D in the spike protein of transmissible gastroenteritis virus and evaluation of their inhibitory effects on viral infection Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus Construction, safety and immunogenicity analysis of attenuated Salmonella typhimurium harbouring TGEV DNA vaccine Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus Expression of swine transmissible gastroenteritis virus envelope antigens on the surface of infected cells: epitopes externally exposed Clinical evaluation of transmissible gastroenteritis virus vaccines and vaccination procedures for inducing lactogenic immunity in sows A monoclonal antibody against transmissible gastroenteritis virus generated via immunization of a DNA plasmid bearing TGEV S1 gene 25 years and counting: Centers for Disease Control and Prevention identifies opportunities and challenges for diabetes prevention and control Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies Recombinant fowlpox virus inducing protective immunity in non-avian species Recombinant swinepox virus expressing betagalactosidase: investigation of viral host range and gene expression levels in cell culture Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein Replication and expression of a swinepox virus vector delivering feline leukemia virus Gag and Env to cell lines of swine and feline origin Feline B7.1 and B7.2 proteins produced from swinepox virus vectors are natively processed and biologically active: potential for use as nonchemical adjuvants First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs A novel vaccine against Streptococcus equi ssp. key: cord-275635-d50bxe7c authors: Yuan, Xiaomin; Lin, Huixing; Fan, Hongjie title: Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein date: 2015-07-31 journal: Vaccine DOI: 10.1016/j.vaccine.2015.06.057 sha: doc_id: 275635 cord_uid: d50bxe7c


id: cord-262940-eyejnexx
author: Liu, Genmei
date: 2013-11-12
extension: .txt
mime: text/plain
words: 3868
sentence: 143
flesch: 44
cache: cache/cord-262940-eyejnexx.txt
txt: txt/cord-262940-eyejnexx.txt
title:
  Assembly and immunogenicity of coronavirus-like particles carrying infectious bronchitis virus M and S proteins

summary:
  Here we report that transfection of Sf9 cells with a single recombinant baculovirus encoding M and S proteins resulted in the assembly of IBV VLPs; this is the first report that S protein plus M protein alone were able to be assembled into VLPs for coronaviruses. Interestingly, when M protein was expressed alone, it could be detected in the sedimentable particles of the culture media ((A), lane 2), but S protein could not be detected when it was expressed alone ((B), lane 2).


id: cord-291510-jh2fdks4
author: Jiang, Yi
date: 2020-02-11
extension: .txt
mime: text/plain
words: 8033
sentence: 304
flesch: 46
cache: cache/cord-291510-jh2fdks4.txt
txt: txt/cord-291510-jh2fdks4.txt
title:
  Recombinant infectious bronchitis coronavirus H120 with the spike protein S1 gene of the nephropathogenic IBYZ strain remains attenuated but induces protective immunity

summary:
  Sheng Zhou: Conceptualization, Validation, Resources, Writing -original draft The long view: 40 years of infectious bronchitis research Coronaviruses in poultry and other birds Review of infectious bronchitis virus around the world Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus Recombinant avian infectious bronchitis virus expressing a heterologous spike gene demonstrates that the spike protein is a determinant of cell tropism Coronavirus avian infectious bronchitis virus Infectious bronchitis virus variants: molecular analysis and pathogenicity investigation Sequence evidence for RNA recombination in field isolates of avian coronavirus infectious bronchitis virus Progress and challenges toward the development of vaccines against avian infectious bronchitis A new genotype of nephropathogenic infectious bronchitis virus circulating in vaccinated and non-vaccinated flocks in China Genetic diversity of avian infectious bronchitis coronavirus in recent years in China Analysis of S1 gene of avian infectious bronchitis virus isolated in southern China during Genetic analysis revealed LX4 genotype strains of avian infectious bronchitis virus became predominant in recent years in Sichuan area Current status of veterinary vaccines Protection of laying hens against infectious bronchitis with inactivated emulsion vaccines Avian infectious bronchitis: the protection afforded by an inactivated virus vaccine IgM responses in chicken serum to live and inactivated infectious bronchitis virus vaccines Molecular characterization and pathogenicity of infectious bronchitis coronaviruses: complicated evolution and epidemiology in china caused by cocirculation of multiple types of infectious bronchitis coronaviruses Molecular characterization of an infectious bronchitis virus strain isolated from northern China in 2012 Safety and efficacy of an attenuated Chinese QX-like infectious bronchitis virus strain as a candidate vaccine Attenuation, safety, and efficacy of a QX-like infectious bronchitis virus serotype vaccine Preparation and protective efficacy of a chicken embryo kidney cell-attenuation GI-19/QX-like avian infectious bronchitis virus vaccine Rapid development and evaluation of a live-attenuated QX-like infectious bronchitis virus vaccine Efficacy and safety of an attenuated live QX-like infectious bronchitis virus strain as a vaccine for chickens Safety and efficacy of an infectious bronchitis virus used for chicken embryo vaccination Embryo vaccination of chickens with infectious bronchitis virus: histologic and ultrastructural lesion response and immunologic response to vaccination Attenuated vaccines can recombine to form virulent field viruses Recombinant infectious bronchitis viruses expressing chimeric spike glycoproteins induce partial protective immunity against homologous challenge despite limited replication in vivo Recombinant live attenuated avian coronavirus vaccines with deletions in the accessory genes 3ab and/or 5ab protect against infectious bronchitis in chickens Recombinant infectious bronchitis viruses expressing heterologous S1 subunits: potential for a new generation of vaccines that replicate in Vero cells Reverse genetics system for the avian coronavirus infectious bronchitis virus Establishment of reverse genetics system for infectious bronchitis virus attenuated vaccine strain H120 Infectious bronchitis virus as a vector for the expression of heterologous genes The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens Construction of an infectious fulllength cDNA clone of infectious bronchitis virus H120 vaccine strain Expression of green fluorescent protein using an infectious cDNA clone of infectious bronchitis virus The causative agent of IB is infectious bronchitis virus (IBV), a non-segmented, positive-sense, single-stranded RNA virus, which belongs to the genus Gammacoronavirus, family Coronaviridae, in the order Nidovirales


id: cord-316839-wckqscvm
author: Maunsell, Fiona P.
title: Field evaluation of a Mycoplasma bovis bacterin in young dairy calves
date: 2009-05-11
extension: .txt
mime: text/plain
words: 7402
sentence: 299
flesch: 49
cache: cache/cord-316839-wckqscvm.txt
txt: txt/cord-316839-wckqscvm.txt
summary:
  Although M. bovis-associated mortality also occurred in Herd C, it was not the primary cause of calf mortality: only 17% (1/6) of mortalities in vaccinated and 36% (4/11) of mortalities in control calves in Herd C were attributable to M. bovis. Nasal colonization was not affected by vaccination; in Herd B where endemic M. bovis disease was present, the mean percentage (±SD) of calves with M. bovis-positive nasal swabs at each sampling time was 81.4 ± 24.4% for vaccinated calves and 75.8 ± 20.0% in control calves.


id: cord-295191-xu26mvc3
author: Avirutnan, Panisadee
title: Complement and its role in protection and pathogenesis of flavivirus infections
date: 2008-12-30
extension: .txt
mime: text/plain
words: 6127
sentence: 219
flesch: 23
cache: cache/cord-295191-xu26mvc3.txt
txt: txt/cord-295191-xu26mvc3.txt
summary:
  lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19 C3d of complement as a molecular adjuvant: bridging innate and acquired immunity Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen Antibody response to a T-dependent antigen requires B cell expression of complement receptors Regulation of the B cell response to T-dependent antigens by classical pathway complement Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2 B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors Dependence of germinal center B cells on expression of CD21/CD35 for survival Impaired affinity maturation in Cr2−/− mice is rescued by adjuvants without improvement in germinal center development Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte Complement receptor 1/CD35 is a receptor for mannan-binding lectin Complement receptor type 1 (CR1 CD35) is a receptor for C1q Expression of C3b receptors on human be cells and myelomonocytic cells but not natural killer cells Both Kupffer cells and liver endothelial cells play an important role in the clearance of IgA and IgG immune complexes Clearance of antidouble-stranded DNA antibodies: the natural immune complex clearance mechanism Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative The murine complement receptor gene family. Evidence for a single gene model of mouse complement receptors 1 and 2 Humoral immune responses in Cr2−/− mice: enhanced affinity maturation but impaired antibody persistence Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses Local synthesis of complement component C3 regulates acute renal transplant rejection Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses C3b covalently associated to tetanus toxin modulates TT processing and presentation by U937 cells Covalent binding of C3b to tetanus toxin: influence on uptake/internalization of antigen by antigen-specific and non-specific B cells Antigen-bound C3b and C4b enhance antigenpresenting cell function in activation of human T-cell clones Modulation of antigen processing and presentation by covalently linked complement C3b fragment B cell receptors and complement receptors target the antigen to distinct intracellular compartments Complement C3b fragment covalently linked to tetanus toxin increases lysosomal sodium dodecyl sulfate-stable HLA-DR dimer production C3b complexation diversifies naturally processed T cell epitopes Maturation of dendritic cells abrogates C1q production in vivo and in vitro Complement protein C1q induces maturation of human dendritic cells Immune modulation of human dendritic cells by complement T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells Immune complex processing in C1q-deficient mice A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+ T lymphocytes Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine Protective immune responses against West Nile virus are primed by distinct complement activation pathways Complement contributes to protective immunity against reinfection by Plasmodium chabaudi chabaudi parasites HIV and human complement: inefficient virolysis and effective adherence Viral mimicry of the complement system Role of complement in immune regulation and its exploitation by virus Virus complement evasion strategies Complement evasion by human pathogens Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18)


id: cord-272292-k0ugjb6f
author: Liu, Shih-Jen
title: Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates
date: 2006-04-12
extension: .txt
mime: text/plain
words: 4978
sentence: 203
flesch: 51
cache: cache/cord-272292-k0ugjb6f.txt
txt: txt/cord-272292-k0ugjb6f.txt
summary:
  Like other viruses with spike proteins on the viral surface, coronaviruses have been shown to elicit enhancement of disease through non-neutralizing spike protein-specific antibodies [3] , so vaccines that elicit T-cell immunity against SARS proteins are likely to receive more-favorable clinical attention. The generation of IgG2a antibodies following DNA immunization of N protein suggested that there was a significant Th1-type response [16] .


id: cord-279985-de0b27nq
author: Anraku, Itaru
title: Kunjin replicon-based simian immunodeficiency virus gag vaccines
date: 2008-06-19
extension: .txt
mime: text/plain
words: 6408
sentence: 221
flesch: 44
cache: cache/cord-279985-de0b27nq.txt
txt: txt/cord-279985-de0b27nq.txt
summary:
  The A20-EGFP-SIV gag challenge model (Fig. 5 ) represents a new model for testing the effectiveness of T cell induction by SIV gag vaccines. The use of peptide pools covering Gag to measure T cell responses in mice has been described previously


id: cord-303056-bdse9o26
author: Okada, Masaji
date: 2007-04-20
extension: .txt
mime: text/plain
words: 1293
sentence: 57
flesch: 49
cache: cache/cord-303056-bdse9o26.txt
txt: txt/cord-303056-bdse9o26.txt
title:
  Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models

summary:
  SARS M DNA vaccine and N DNA vaccine induced human CTL specific for SARS CoV antigens. Alternatively, SARS M DNA vaccines inducing human neutralizing antibodies and human monoclonal antibodies against SARS CoV are now being developed.


id: cord-260667-5aurua6o
author: Falchieri, Marco
date: 2013-05-24
extension: .txt
mime: text/plain
words: 3818
sentence: 164
flesch: 45
cache: cache/cord-260667-5aurua6o.txt
txt: txt/cord-260667-5aurua6o.txt
title:
  Avian metapneumoviruses expressing Infectious Bronchitis virus genes are stable and induce protection

summary:
  Predictive computational comparison of S1 populations S1 genes with and without the deletion were compared. While virus AvF containing N gene alone or N + S1 genes together protected tracheas better than AvF containing the S1 gene alone, the expression of the inserted genes would need to be quantified, before conclusions about the relative contribution of each gene to protection, could be drawn.


id: cord-261274-y74smbtd
author: Crouch, C. F
title: Lactogenic immunity following vaccination of cattle with bovine coronavirus
date: 2000-09-15
extension: .txt
mime: text/plain
words: 4178
sentence: 145
flesch: 48
cache: cache/cord-261274-y74smbtd.txt
txt: txt/cord-261274-y74smbtd.txt
summary:
  The eect of the interval between vaccination and calving on the increase in milk VN antibody titre can be seen in Table 1 where data from studies A and B have been combined into ®ve sets, each set comprising 12 cows (three vaccinate and three placebo cows from each study) with mean vaccination/calving intervals of 19, 30, 46, 69 and 85 days, respectively. Associated with this increase in serum VN antibody levels, ®rst day colostrum VN antibody was also signi®cantly higher log 10 0X5±0X8 in the test vaccine groups compared with the placebo control groups.


id: cord-271514-sls3bsm0
author: Dean, Natalie E.
title: Ensemble Forecast Modeling for the Design of COVID-19 Vaccine Efficacy Trials
date: 2020-09-15
extension: .txt
mime: text/plain
words: 2501
sentence: 105
flesch: 36
cache: cache/cord-271514-sls3bsm0.txt
txt: txt/cord-271514-sls3bsm0.txt
summary:
  key: cord-271514-sls3bsm0 authors: Dean, Natalie E.; Pastore y Piontti, Ana; Madewell, Zachary J.; Cummings, Derek A.T; Hitchings, Matthew D.T.; Joshi, Keya; Kahn, Rebecca; Vespignani, Alessandro; Elizabeth Halloran, M.; Longini, Ira M. title: Ensemble Forecast Modeling for the Design of COVID-19 Vaccine Efficacy Trials date: 2020-09-15 journal: Vaccine DOI: 10.1016/j.vaccine.2020.09.031 sha: doc_id: 271514 cord_uid: sls3bsm0 To rapidly evaluate the safety and efficacy of COVID-19 vaccine candidates, prioritizing vaccine trial sites in areas with high expected disease incidence can speed endpoint accrual and shorten trial duration. Selecting vaccine trial sites where disease incidence is highest during the study period can accelerate the accrual of endpoints.


id: cord-294302-hboc3xcz
author: Roncati, Luca
title: COVID-19 vaccine and boosted immunity: nothing ad interim to do?
date: 2020-10-09
extension: .txt
mime: text/plain
words: 2276
sentence: 98
flesch: 32
cache: cache/cord-294302-hboc3xcz.txt
txt: txt/cord-294302-hboc3xcz.txt
summary:
  Through C. parvum vaccine (point 3), it is theoretically possible to train and calibrate the immune system towards a T h 1 response (point 4), able to prevent COVID-19 or to keep the disease under control in a paucisymptomatic or asymptomatic way thanks to activated reticuloendothelial system, NK, T c and dendritic cells. In addition, a scientific evidence of C. parvum vaccine protection against a coronavirus (mouse hepatitis virus type 3), dating back to 1981 murine model by Schindler and colleagues, is also reported [31] .


id: cord-271734-1cfhjuxi
author: Vergkizi, Souzan
date: 2020-10-16
extension: .txt
mime: text/plain
words: 5711
sentence: 214
flesch: 42
cache: cache/cord-271734-1cfhjuxi.txt
txt: txt/cord-271734-1cfhjuxi.txt
title:
  Bacillus Calmette–Guérin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally

summary:
  Following the unresponsiveness of BCG induced cervical lymph nodes to soluble mycobacterial antigens, it was thought worthwhile to check the response of lymph node cells of BCG and M. leprae injected animals to whole BCG organisms. In each group, the first two bars (a, b) correspond to BCG and the last two (c, d) to M. leprae induced lymph node cells.


id: cord-266745-jit1xeqc
author: Liou, Jenn-Fa
title: Passive protection effect of chicken egg yolk immunoglobulins on enterovirus 71 infected mice
date: 2010-11-29
extension: .txt
mime: text/plain
words: 5726
sentence: 242
flesch: 49
cache: cache/cord-266745-jit1xeqc.txt
txt: txt/cord-266745-jit1xeqc.txt
summary:
  The mortality among specific IgY treated mice was 24% (10/41), which was significantly lower than that of the control group, at 69% (33/48). In 1998, an outbreak of EV71 infections occurred in Taiwan, in which 405 children were hospitalized and 78 died [15] .


id: cord-294789-07hto8qn
author: Schoch-Spana, Monica
date: 2020-10-29
extension: .txt
mime: text/plain
words: 5812
sentence: 228
flesch: 33
cache: cache/cord-294789-07hto8qn.txt
txt: txt/cord-294789-07hto8qn.txt
title:
  The public’s role in COVID-19 vaccination: human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States

summary:
  A combination of literature reviews on vaccination, pandemic planning, and health crisis communication; an assessment of current news and social media trends regarding COVID-19 vaccines; and key informant interviews with each working group member focusing on their respective expertise formed the basis of the research presented in this article. In the case of SARS-CoV-2 vaccination, for instance, while an NIH Funding Opportunity Award that could support research on human factors related to vaccine acceptance was made possible in June 2020, the earliest project start date is September 2021, a full nine months after Operation Warp Speed plans for COVID-19 vaccines to become available [21] .


id: cord-271076-436nxsua
author: Paul-Pierre, Pastoret
title: Emerging diseases, zoonoses and vaccines to control them
date: 2009-10-30
extension: .txt
mime: text/plain
words: 3723
sentence: 147
flesch: 39
cache: cache/cord-271076-436nxsua.txt
txt: txt/cord-271076-436nxsua.txt
summary:
  Misset uitgeverij Factors influencing the antibody response of dogs vaccinated against rabies Genetic and phenotypic correlation between antibody response to Escherichia coli, infectious bursa disease (IBDV), and Newcastle disease virus (NDV), in broiler lines selected on antibody response to Escherichia coli La faune sauvage et les maladies Ã©mergentes The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses Regulatory issues surrounding the temporary authorisation of animal vaccination in emergency situations: the example of bluetongue in Nipah virus infection of pigs in peninsular Malaysia Recombinant nipah virus vaccines protect pigs against challenge Antigen and vaccine bank: technical requirements and the role of the European antigen bank in emergency foot and mouth disease vaccination Control strategies for highly pathogenic avian influenza: a global perspective Animal genomics for animal health West Nile virus and North America: an unfolding story Rift valley fever The impact of climate change on the epidemiology and control of Rift Valley fever Genetic characterization of Toggenburg Orbivirus, a new bluetongue virus, from goats in Switzerland. It is even more true when facing a really emerging disease that moreover is zoonotic such as Nipah virus infection [27] for which no vaccine was available yet, because the causative agent was previously unknown; the only solution is once again to kill and destroy the infected and in-contact animals.


id: cord-271650-biq0chyn
author: Torres, Juan M
date: 2000-09-15
extension: .txt
mime: text/plain
words: 4621
sentence: 184
flesch: 41
cache: cache/cord-271650-biq0chyn.txt
txt: txt/cord-271650-biq0chyn.txt
title:
  Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease

summary:
  The history and biology of a successful coloniser Myxoma virus in rabbits Protection of laboratory rabbits against myxomatosis by vaccination with ®broma virus Etude d'une souche de virus myxomateux modi®e A new viral disease in rabbits Hepatitis of viral origin in leporidae: introduction and aetiological hypotheses Rabbit haemorrhagic disease (RHD): characterization of the causative calicivirus Incidence of viral haemorrhagic disease in wild rabbit populations in Spain Rabbit haemorrhagic disease: the new scourge of Oryctolagus cuniculus Impact of viral haemorrhagic disease on a wild population of European rabbits in France The initial impact of rabbit haemorrhagic disease on European rabbit populations in South Australia Virus taxonomy Ð San Diego Viral haemorrhagic disease of rabbits: vaccination and immune response Molecular cloning, sequencing and expression in Escherichia coli of the capsid protein gene from rabbit haemorrhagic disease virus (Spanish isolate AST/89) Recombinant rabbit haemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection Oral immunization of rabbits with VP60 particles confers protection against rabbit haemorrhagic disease Two independent pathways of expression lead to self-assembly of the rabbit haemorrhagic disease virus capsid protein Protection of rabbits against rabbit viral haemorrhagic disease with a vaccinia-RHDV recombinant virus Protection against myxomatosis and rabbit viral haemorrhagic disease with recombinant myxoma viruses expressing rabbit haemorrhagic disease virus capsid protein A recombinant canarypox virus protects rabbits against a lethal rabbit haemorrhagic disease virus (RHDV) challenge A single dose immunization with rabbit haemorrhagic disease virus major capsid protein produced in Saccharomyces cerevisiae induces protection Immunization with potato plants expressing VP60 protein protects against rabbit haemorrhagic disease virus Isolation of an attenuated myxoma virus ®eld strain that confers horizontal transmissible protection against myxomatosis on contacts of vaccinates Horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease using a recombinant myxoma virus Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America Construction of recombinant myxoma viruses expressing foreign genes from dierent intergenic sites without associated attenuation Transient dominant selection of recombinant vaccinia viruses Immunosuppressive eect of corticosteroids on rabbit's humoral and cellular response ContribucioÂ n a la pro®laxis de la mixomatosis del conejo mediante el uso de una cepa The etiological agent, rabbit haemorrhagic disease virus (RHDV), is a member of the Caliciviridae family


id: cord-255625-4r6ng57a
author: Graffigna, Guendalina
title: “Cultivating” acceptance of a COVID-19 vaccination program: Lessons from Italy
date: 2020-11-10
extension: .txt
mime: text/plain
words: 631
sentence: 24
flesch: 41
cache: cache/cord-255625-4r6ng57a.txt
txt: txt/cord-255625-4r6ng57a.txt
summary:
  Results of our study showed that 41% of the participants reported to be unwilling or hesitant towards COVID-19 vaccine. Citizens need to be engaged in a deep process of psychological acceptance, in order to adopt a socially responsible approach to COVID-19 preventive behaviors [4, 5] .


id: cord-255026-fdp6mies
author: Belák, Sándor
date: 2007-07-26
extension: .txt
mime: text/plain
words: 5344
sentence: 191
flesch: 36
cache: cache/cord-255026-fdp6mies.txt
txt: txt/cord-255026-fdp6mies.txt
title:
  Molecular diagnosis of viral diseases, present trends and future aspects: A view from the OIE Collaborating Centre for the Application of Polymerase Chain Reaction Methods for Diagnosis of Viral Diseases in Veterinary Medicine

summary:
  The real-time PCR assays provide novel rapid means of virus detection in the diagnostic laboratories. By introducing single and nested PCR assays as early as 1987-1988, two years after the description of the PCR principle, our laboratory was among the first ones to use this technique for diagnostic purposes [2, 3] .


id: cord-279841-oq25o4qr
author: Ahlquist, Paul
title: Viral and host determinants of RNA virus vector replication and expression
date: 2005-03-07
extension: .txt
mime: text/plain
words: 2272
sentence: 72
flesch: 27
cache: cache/cord-279841-oq25o4qr.txt
txt: txt/cord-279841-oq25o4qr.txt
summary:
  key: cord-279841-oq25o4qr authors: Ahlquist, Paul; Schwartz, Michael; Chen, Jianbo; Kushner, David; Hao, Linhui; Dye, Billy T. title: Viral and host determinants of RNA virus vector replication and expression date: 2005-03-07 journal: Vaccine DOI: 10.1016/j.vaccine.2004.11.005 sha: doc_id: 279841 cord_uid: oq25o4qr Positive-strand RNA viruses have proven to be valuable vectors for delivery and expression of antigens for direct vaccination of animals and vaccine production in plants. One virus that is being used as a model to study positivestrand RNA virus replication is brome mosaic virus (BMV).


id: cord-342405-nsj9dh48
author: Chakraborty, Chiranjib
title: India’s cost-effective COVID-19 vaccine development initiatives
date: 2020-10-20
extension: .txt
mime: text/plain
words: 523
sentence: 23
flesch: 47
cache: cache/cord-342405-nsj9dh48.txt
txt: txt/cord-342405-nsj9dh48.txt
summary:
  India has a long history of vaccine production and the Haffkine Institute 1 for example has been recognized by the WHO as a prequalified vaccines producer before the country got Institute of India 5 has long history of producing vaccines against tetanus, influenza, rabies, measles, and mumps. key: cord-342405-nsj9dh48 authors: Chakraborty, Chiranjib; Agoramoorthy, Govindasamy title: India’s cost-effective COVID-19 vaccine development initiatives date: 2020-10-20 journal: Vaccine DOI: 10.1016/j.vaccine.2020.10.056 sha: doc_id: 342405 cord_uid: nsj9dh48 nan The creation of cost effective vaccine is fundamental for the effective mitigation of the deadly COVID-19 pandemic.


id: cord-303200-hwvkvdlk
author: Decaro, Nicola
date: 2007-01-26
extension: .txt
mime: text/plain
words: 2727
sentence: 113
flesch: 50
cache: cache/cord-303200-hwvkvdlk.txt
txt: txt/cord-303200-hwvkvdlk.txt
title:
  Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: A clinical and laboratory diagnostic dilemma

summary:
  Specimens that tested positive for CPV vaccine strains and negative for viral pathogens were examined for bacterial and parasitic pathogens by standardised methods. On the other hand, the novel MGB probe assays represent an effective tool for rapid discrimination between vaccine and field strains of CPV-2 since they are able to detect vaccine and field strains that occur simultaneously in the faeces of vaccinated dogs, even when low titres of vaccine strains are shed


id: cord-277054-eq4obbte
author: Kaur, Manpreet
date: 2009-03-26
extension: .txt
mime: text/plain
words: 6916
sentence: 307
flesch: 40
cache: cache/cord-277054-eq4obbte.txt
txt: txt/cord-277054-eq4obbte.txt
title:
  Rabies DNA vaccine: No impact of MHC Class I and Class II targeting sequences on immune response and protection against lethal challenge

summary:
  key: cord-277054-eq4obbte authors: Kaur, Manpreet; Rai, Anant; Bhatnagar, Rakesh title: Rabies DNA vaccine: No impact of MHC Class I and Class II targeting sequences on immune response and protection against lethal challenge date: 2009-03-26 journal: Vaccine DOI: 10.1016/j.vaccine.2009.01.128 sha: doc_id: 277054 cord_uid: eq4obbte Rabies is progressive fatal encephalitis. Rabies DNA vaccine has also been found to be highly efficient in large size mammals [21] .


id: cord-304807-j2k1oel2
author: Herrera-Rodriguez, José
date: 2019-03-14
extension: .txt
mime: text/plain
words: 5764
sentence: 219
flesch: 38
cache: cache/cord-304807-j2k1oel2.txt
txt: txt/cord-304807-j2k1oel2.txt
title:
  Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production

summary:
  The first step in the production process is virus inactivation with β-propiolactone (BPL) or formaldehyde (FA). For all the other types of vaccines derived from whole viral particles, a crucial step in production is virus inactivation.


id: cord-252293-8286lsof
author: Suzuki, Motoi
date: 2018-05-17
extension: .txt
mime: text/plain
words: 4074
sentence: 186
flesch: 37
cache: cache/cord-252293-8286lsof.txt
txt: txt/cord-252293-8286lsof.txt
title:
  Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

summary:
  Influenza pneumonia patients were classified as having influenza-associated bacterial pneumonia if their sputum samples were microscopically purulent (i.e., Geckler's classification groups 4 and 5) and tested positive for bacterial pathogens by culture or PCR; otherwise, they were classified as having primary influenza pneumonia. Demographic and clinical characteristics were compared between influenza pneumonia patients (i.e., cases) and noninfluenza pneumonia patients (i.e., controls) (Tables 1 and 2 ).


id: cord-302222-9ad0fw6z
author: Monath, Thomas P.
title: Vaccines against diseases transmitted from animals to humans: A one health paradigm
date: 2013-11-04
extension: .txt
mime: text/plain
words: 15731
sentence: 580
flesch: 35
cache: cache/cord-302222-9ad0fw6z.txt
txt: txt/cord-302222-9ad0fw6z.txt
summary:
  The complexity, timeline, and cost of development of animal vaccines and the regulatory hurdles for product approval are far less than for human vaccines. As mentioned above, the regulatory pathway for animal vaccines is considerably simpler than for human vaccines [201] .


id: cord-315437-h6xjudm0
author: Nyon, Mun Peak
title: Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
date: 2018-03-27
extension: .txt
mime: text/plain
words: 6656
sentence: 229
flesch: 42
cache: cache/cord-315437-h6xjudm0.txt
txt: txt/cord-315437-h6xjudm0.txt
summary:
  While these mAbs bound strongly to the non-denatured (no DTT) S377-588-Fc proteins expressed in both adCHO and HEK293T, they had significantly reduced affinity to RBD proteins treated with DTT, a reducing agent cleaving disulfide bonds of RBDs and thus disrupting a protein's native conformation (Fig. 4e) . Middle East respiratory syndrome coronavirus The middle east respiratory syndrome coronavirus -a continuing risk to global health security Vaccine development against prioritized epidemic infectious diseases Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases Innate immune signaling by, and genetic adjuvants for DNA vaccination The future of human DNA vaccines Receptor recognition mechanisms of coronaviruses: a decade of structural studies Middle East respiratory syndrome: current status and future prospects for vaccine development Vaccines for the prevention against the threat of MERS-CoV Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome Receptor-binding domain-based subunit vaccines against MERS-CoV Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus Recombinant receptorbinding domains of multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines Characteristics of early-and lateonset rapid eye movement sleep behavior disorder in China: a case-control study Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease Evaluation of stable and highly productive gene amplified CHO cell line based on the location of amplified genes A recombinant receptorbinding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection Junctional and allelespecific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus Optimized signal peptides for the development of high expressing CHO cell lines MERS-CoV spike protein: a key target for antivirals Evaluation of transfection methods for transient gene expression in Chinese hamster ovary cells Gene expression in Mammalian cells and its applications Designing CD4 immunoadhesins for AIDS therapy Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice A neonatal Fc receptortargeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice Fc-fusion proteins: new developments and future perspectives Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds A plea to reduce or replace fetal bovine serum in cell culture media Advances in Mammalian cell line development technologies for recombinant protein production Identification of a receptorbinding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction This study was supported through the US-Malaysian Vaccine Development Program, funded by the University of Malaya, and grants from the NIH (R01AI098775-03S1 and R21AI128311).


id: cord-270910-xb746mv5
author: Lebrun-Harris, Lydie A.
date: 2020-07-24
extension: .txt
mime: text/plain
words: 5239
sentence: 186
flesch: 31
cache: cache/cord-270910-xb746mv5.txt
txt: txt/cord-270910-xb746mv5.txt
title:
  Influenza vaccination among U.S. pediatric patients receiving care from federally funded health centers

summary:
  Third, although influenza vaccines are recommended for infants starting at 6 months, it was not possible to examine vaccination among health center patients younger than 2 years because of how age was coded in the dataset; therefore we were unable to obtain estimates of influenza vaccination for this age group. What is a Health Center New Census Data Show Differences Between Urban and Rural Populations Number of children Key facts about the number of children How to improve influenza vaccination rates in the U.S. J Prevent Med Public Health = Yebang Uihakhoe chi Flu-Floppers: Factors Influencing Families' Fickle Flu Vaccination Patterns Vaccine hesitancy and influenza beliefs among parents of children requiring a second dose of influenza vaccine in a season: An American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) study Partnering with parents to remove barriers and improve influenza immunization rates for young children An assessment of parental knowledge, attitudes, and beliefs regarding influenza vaccination What is 'confidence' and what could affect it?


id: cord-260761-ngms51ie
author: Sawada, Akihito
date: 2011-02-04
extension: .txt
mime: text/plain
words: 6581
sentence: 281
flesch: 48
cache: cache/cord-260761-ngms51ie.txt
txt: txt/cord-260761-ngms51ie.txt
title:
  AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats

summary:
  Recombinant MVAIK expressing RSV F protein is a promising candidate and protective effects should be confirmed in monkey model, considering the immunization routes. Recombinants expressing RSV F or G was highly immunogenic, induced protection in mouse but provided inconsistent protection in chimpanzees [37] .


id: cord-010279-ytnv0map
author: Bahnemann, Hans G.
date: 2002-11-12
extension: .txt
mime: text/plain
words: 3484
sentence: 147
flesch: 41
cache: cache/cord-010279-ytnv0map.txt
txt: txt/cord-010279-ytnv0map.txt
title:
  Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine

summary:
  A recent publication stating the linearity of formaldehyde inactivation of FMD virus 5 comes to this erroneous conclusion because the infectivity titration for the inactivation slope was based on final readings of plaque forming units (p.f.u.) Other laboratories continued to work on FMD virus inactivation by aziridines and in the early 1970s reports on ethylethylenimine, EEI zg, ethylenimine, E127 and binary ethylenimine, BEI 3° were published.


id: cord-325998-87l6nixc
author: Wong, J.P.
title: Activation of toll-like receptor signaling pathway for protection against influenza virus infection
date: 2009-05-26
extension: .txt
mime: text/plain
words: 2217
sentence: 92
flesch: 47
cache: cache/cord-325998-87l6nixc.txt
txt: txt/cord-325998-87l6nixc.txt
summary:
  For the prophylaxis of influenza virus infection, groups of mice (8-10 animals per group) were given two doses of free or liposomal poly ICLC (1 mg/kg body weight) Animal studies suggest that activation of TLR signaling pathway by TLR agonists provides protection not only against influenza virus infections, but also respiratory syncytial virus


id: cord-278598-3utk3k6z
author: Tarpey, I.
title: Safety and efficacy of an infectious bronchitis virus used for chicken embryo vaccination
date: 2006-11-17
extension: .txt
mime: text/plain
words: 4826
sentence: 201
flesch: 57
cache: cache/cord-278598-3utk3k6z.txt
txt: txt/cord-278598-3utk3k6z.txt
summary:
  As uniform mass application of IBV vaccines post hatch can be problematic with regard to obtaining even distribution of spray or ensuring all birds receive the correct dosage from drinking water, delivering IBV in ovo, via which a precise dosage can be achieved, could bring significant advantages to the poultry industry. In contrast to commercial IBV vaccines given in ovo, the Beau-R and BeauR-M41(S) strains did not reduce hatchability or cause nasal discharge, and caused minimal damage to the ciliated epithelium of the trachea.


id: cord-328698-eeg1k5a6
author: Detoc, Maëlle
date: 2020-09-17
extension: .txt
mime: text/plain
words: 2525
sentence: 111
flesch: 44
cache: cache/cord-328698-eeg1k5a6.txt
txt: txt/cord-328698-eeg1k5a6.txt
title:
  Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

summary:
  Vaccine hesitancy may also have an impact on recruitment in COVID-19 vaccine clinical trial [7] . The impact of the current pandemic on the intention to participate in a COVID-19 vaccine clinical trial and on the intention to get vaccinated against COVID-19 vaccine is not obvious.


id: cord-273526-ah0dvnxv
author: Cao, Weiping
date: 2017-06-05
extension: .txt
mime: text/plain
words: 4409
sentence: 171
flesch: 38
cache: cache/cord-273526-ah0dvnxv.txt
txt: txt/cord-273526-ah0dvnxv.txt
title:
  Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice

summary:
  Our findings suggest that nasal delivery of H5N1 vaccine with Protollin adjuvant can overcome the poor immunogenicity of H5N1 vaccines, induce both cellular and humoral immune responses, enhance protection against challenge with clade 1 and clade 2 H5N1 viruses and achieve significant antigen dose-sparing. The inherently poor immunogenicity of unadjuvanted H5N1 influenza vaccines warranted efforts to explore novel adjuvants and alternate delivery systems to improve immunogenicity and protective efficacy of H5N1 vaccines.


id: cord-330406-a1tvcgqj
author: Moore, George E.
title: A space–time cluster of adverse events associated with canine rabies vaccine
date: 2005-12-01
extension: .txt
mime: text/plain
words: 3231
sentence: 121
flesch: 40
cache: cache/cord-330406-a1tvcgqj.txt
txt: txt/cord-330406-a1tvcgqj.txt
summary:
  This covariate did not fully explain the VAE increase in the detected cluster, indicating further investigations are warranted to determine other potential risk factors associated with cluster events. key: cord-330406-a1tvcgqj authors: Moore, George E.; Ward, Michael P.; Kulldorff, Martin; Caldanaro, Richard J.; Guptill, Lynn F.; Lewis, Hugh B.; Glickman, Lawrence T. title: A space–time cluster of adverse events associated with canine rabies vaccine date: 2005-12-01 journal: Vaccine DOI: 10.1016/j.vaccine.2005.07.041 sha: doc_id: 330406 cord_uid: a1tvcgqj Electronic medical records of a large veterinary practice were used for surveillance of potential space–time clustering of adverse events associated with rabies vaccination in dogs.


id: cord-322505-6q92742u
author: Basinski, Andrew J.
title: Evaluating the promise of recombinant transmissible vaccines
date: 2017-12-24
extension: .txt
mime: text/plain
words: 4188
sentence: 143
flesch: 34
cache: cache/cord-322505-6q92742u.txt
txt: txt/cord-322505-6q92742u.txt
summary:
  For instance, if infection with the vector does not confer vaccine immunity to hosts, or if the vector is absent from the population altogether, our results show that a RTV can autonomously sweep through a host population and eradicate an endemic infectious pathogen or provide prophylaxis against a future epidemic. We use the subsystem consisting of equations 5a, 5c, 5d, 5h, 5k to describe cases in which the vector does not impart vaccine immunity to hosts, and the full model to describe cases in which vector/vaccine cross-immunity is perfect.


id: cord-336730-hqgwj8vs
author: Fehr, Daniela
date: 1997-07-31
extension: .txt
mime: text/plain
words: 4309
sentence: 173
flesch: 52
cache: cache/cord-336730-hqgwj8vs.txt
txt: txt/cord-336730-hqgwj8vs.txt
title:
  Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions

summary:
  However, if the incidence of FIP cases during the first 150 days after vaccination were compared in vaccinated vs placebo cats, there is absolutely no difference in that 12 cats in the vaccine group and 11 cats in the placebo group died during this time. Under experimental conditions, vaccination of FCoV naive cats was also found to reduce the incidence and the severity of infections with the low virulent viruses called FECV38.


id: cord-313911-lfn9ggg3
author: Kenner, Julie
title: LC16m8: An attenuated smallpox vaccine
date: 2006-11-17
extension: .txt
mime: text/plain
words: 7968
sentence: 318
flesch: 38
cache: cache/cord-313911-lfn9ggg3.txt
txt: txt/cord-313911-lfn9ggg3.txt
summary:
  The frequency of moderate to severe adverse reactions associated with smallpox vaccines currently stockpiled in the US, and the continued threat of bioterrorism have prompted the development of effective vaccines with improved safety profiles. This discovery has further fueled the drive to identify smallpox vaccines with improved safety profiles.


id: cord-349309-7xsbpid7
author: Condit, Richard C
date: 2020-09-06
extension: .txt
mime: text/plain
words: 2058
sentence: 75
flesch: 36
cache: cache/cord-349309-7xsbpid7.txt
txt: txt/cord-349309-7xsbpid7.txt
title:
  The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

summary:
  The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. Pursuant to this goal, the V3SWG developed a standardized template that the Coalition for Epidemic Preparedness Innovations (CEPI) and other key stakeholders could use to evaluate and communicate key considerations for the benefit-risk assessment of viral vectors and viral vector vaccines.


id: cord-332358-0t4uxmj2
author: Lamphear, Barry J.
date: 2004-06-23
extension: .txt
mime: text/plain
words: 3131
sentence: 118
flesch: 41
cache: cache/cord-332358-0t4uxmj2.txt
txt: txt/cord-332358-0t4uxmj2.txt
title:
  A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine

summary:
  However, replacing subsequent injections of the modified live TGEV vaccine with oral corn vaccine boosters would clearly save considerable time and effort. Cereals are particularly well-suited expression vehicles since the expressed proteins can be stored at relatively high concentrations for extended periods of time without degradation and dry seed can be formulated into oral vaccines suitable for commercial applications.


id: cord-344316-mwnnmwnw
author: Herst, C.V.
date: 2020-04-28
extension: .txt
mime: text/plain
words: 3507
sentence: 129
flesch: 40
cache: cache/cord-344316-mwnnmwnw.txt
txt: txt/cord-344316-mwnnmwnw.txt
title:
  An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

summary:
  bioinformatics Anti-spike igg causes severe acute lung injury by skewing macrophage responses during acute sars-cov infection T-cell immunity of sars-cov: Implications for vaccine development against mers-cov Flow focusing: a versatile technology to produce size-controlled and specific-morphology microparticles Human ebola virus infection results in substantial immune activation Immunopathogenesis of severe acute respiratory disease in zaire ebolavirus-infected pigs Reliable prediction of t-cell epitopes using neural networks with novel sequence representations Synthetic peptides coupled to the surface of liposomes effectively induce sars coronavirus-specific cytotoxic t lymphocytes and viral clearance in hla-a* 0201 transgenic mice Long-lived memory t lymphocyte responses against sars coronavirus nucleocapsid protein in sarsrecovered patients Hiv control is mediated in part by cd8+ t-cell targeting of specific epitopes Ebola: an analysis of immunity at the molecular level Large scale analysis of peptide -hla-i stability Large scale analysis of peptide -hla-i stability T cell responses to viral infectionsopportunities for peptide vaccination Eliciting cytotoxic t-lymphocyte responses from synthetic vectors containing one or two epitopes in a c57bl/6 mouse model using peptide-containing biodegradable microspheres and adjuvants Conserved peptide vaccine candidates containing multiple ebola nucleoprotein epitopes display interactions with diverse hla molecules Analysis of cd8+ t cell response during the 2013-2016 ebola epidemic in west africa Phase 1 trials of rvsv ebola vaccine in africa and europe Peptide binding to the most frequent hla-a class i alleles measured by quantitative molecular binding assays Measurement of mhc/peptide interactions by gel filtration or monoclonal antibody capture Viral-induced enhanced disease illness Heterosubtypic t-cell immunity to influenza in humans: Challenges for universal t-cell influenza vaccines Cellular immune correlates of protection against symptomatic pandemic influenza The International HIV Controllers Study et al. For HIV and EBOV and influenza in particular, the potential of CTL vaccines has been discussed [21]


id: cord-323540-7b2mt1a8
author: García, Leidy Y.
title: Contingent assessment of the COVID-19 vaccine
date: 2020-06-25
extension: .txt
mime: text/plain
words: 4015
sentence: 146
flesch: 46
cache: cache/cord-323540-7b2mt1a8.txt
txt: txt/cord-323540-7b2mt1a8.txt
summary:
  The Keywords: COVID-19; SARS-CoV-2; vaccine; acceptance; health economics; contingent valuation The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a pandemic coronavirus disease 2019 (COVID- 19) has had a negative impact on people's health and life and on economies around the world. The vaccine is expected to be available free of charge to at least the poorest people with financing from the governments of each country, while the richest people could voluntarily seek vaccines in private clinics.


id: cord-345191-nabxpyw3
author: Bell, Sadie
date: 2020-10-19
extension: .txt
mime: text/plain
words: 1958
sentence: 60
flesch: 37
cache: cache/cord-345191-nabxpyw3.txt
txt: txt/cord-345191-nabxpyw3.txt
title:
  Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England

summary:
  To prevent inequalities in uptake, it is crucial to understand and address factors that may affect COVID-19 vaccine acceptability in ethnic minority and lower-income groups who are disproportionately affected by COVID-19. The following reasons were given for COVID-19 vaccine acceptance for self and for 253 child/children, in order of how often they were mentioned by survey participants and 254 importance to interviewees.


id: cord-260145-grz0fe9l
author: Liu, Shengwang
date: 2009-07-23
extension: .txt
mime: text/plain
words: 7524
sentence: 308
flesch: 48
cache: cache/cord-260145-grz0fe9l.txt
txt: txt/cord-260145-grz0fe9l.txt
title:
  Altered pathogenicity, immunogenicity, tissue tropism and 3′-7 kb region sequence of an avian infectious bronchitis coronavirus strain after serial passage in embryos

summary:
  Episodic evolution mediates interspecies transfer of a murine coronavirus Altered pathogenesis of a mutant of the murine coronavirus MHV-A59 is associated with a q159L amino acid substitution in the spike protein Targeted recombination within the spike gene of murine coronavirus mouse hepatitis virus-A59: Q159 is a determinant of hepatotropism Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence Murine coronavirus spike glycoprotein mediates degree of viral spread, inflammation, and virus-induced immunopathology in the central nervous system Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein Two amino acid changes at the Nterminus of transmissible gastroenteritis coronavirus spike protein result in the loss of enteric tropism Targeted recombination demonstrates that the spike gene of transmissible gastroenteritis coronavirus is a determinant of its enteric tropism and virulence Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 Gene 5 of the avian coronavirus infectious bronchitis virus is not essential for replication A new genotype of nephropathogenic infectious bronchitis virus circulating in vaccinated and non-vaccinated flocks in China Genetic diversity of avian infectious bronchitis coronavirus strains isolated in China between Sequence analysis of nephropathogenic infectious bronchitis virus strains of the Massachusetts genotype in Beijing Molecular epidemiology of infectious bronchitis virus isolates from China and Southeast Asia Growth kinetics of embryo-and organ-culture adapted Beaudette strain of infectious bronchitis virus in embryonated chicken eggs Transmission of infectious bronchitis virus within vaccinated and unvaccinated groups of chickens Infectious bronchitis virus: S1 gene characteristics of vaccines used in China and efficacy of vaccination against heterologous strains from China Isolation of avian infectious bronchitis coronavirus from domestic peafowl (Pavo cristatus) and teal (Anas) Molecular epizootiology of avian infectious bronchitis in Russia New variant of IBV in Poland New genotype of infectious bronchitis virus in chickens in Scotland Chinese QX strain of infectious bronchitis virus isolated in the UK Detection of infectious bronchitis virus by real-time reverse transcriptase-polymerase chain reaction and identification of a quasispecies in the Beaudette strain Quasispecies of bovine enteric and respiratory coronaviruses based on complete genome sequences and genetic changes after tissue culture adaptation Variation in the spike protein of the 793/B type of infectious bronchitis virus, in the field and during alternate passage in chickens and embryonated eggs Sequence changes of infectious bronchitis virus isolates in the 3 7.3 kb of the genome after attenuating passage in embryonated eggs Transmissible gastroenteritis coronavirus gene 7 is not essential but influences in vivo virus replication and virulence Comparison of four regions in the replicase gene of heterologous infectious bronchitis virus strains Molecular characterization of infectious bronchitis virus isolates foreign to the United States and comparison with United States isolates Rapid selection in chickens of subpopulations within ArkDPI-derived infectious bronchitis virus vaccines Recombinant infectious bronchitis coronavirus Beaudette with the spike protein gene of the pathogenic M41 strain remains attenuated but induces protective immunity A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo Single-aminoacid substitutions in open reading frame (ORF) 1b-nsp14 and ORF 2a proteins of the coronavirus mouse hepatitis virus are attenuating in mice The amino and carboxyl domains of the infectious bronchitis virus nucleocapsid protein interact with 3 genomic RNA Novel variation in the N protein of avian infectious bronchitis virus A comparative sequence ananlysis to revise the current taxonomy of the family coronaviridae The molecular biology of coronaviruses Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus Infectious bronchitis The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex Coronavirus avian infectious bronchitis virus Completion of the sequence of the genome of the coronavirus avian infectious bronchitis virus Infectious bronchitis viruses with a novel genomic organization Identification of the avian infectious bronchitis coronaviruses with mutations in gene 3 A polycistronic mRNA specified by the coronavirus infectious bronchitis virus Identification of a new membrane associated polypeptide specified by the coronavirus infectious bronchitis virus Association of the infectious bronchitis virus 3c protein with the virion envelope Neither the RNA nor the proteins of open reading frames 3a and 3b of the coronavirus infectious bronchitis virus are essential for replication Emergence of a coronavirus infectious bronchitis virus mutant with a truncated 3b gene: functional characterization of the 3b protein in pathogenesis and replication Effect of serial embryo passage of an Arkansas-type avian infectious bronchitis virus isolate on clinical response, virus recovery, and immunity Attenuation, safety, and efficacy of an infectious bronchitis virus GA98 serotype vaccine Development and use of the H strain of avian infectious bronchitis virus from the Netherlands as a vaccine: a review Development of attenuated vaccines from Taiwanese infectious bronchitis virus strains S1 gene sequence heterogeneity of a pathogenic infectious bronchitis virus strain and its embryo-passaged, attenuated derivatives The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system MHV-A59 fusion mutants are attenuated and display altered hepatotropism


id: cord-331900-xtwqv4fk
author: Hussain, Althaf I.
date: 2010-05-14
extension: .txt
mime: text/plain
words: 4819
sentence: 189
flesch: 47
cache: cache/cord-331900-xtwqv4fk.txt
txt: txt/cord-331900-xtwqv4fk.txt
title:
  Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells()

summary:
  In NCI H292 cells virus replication was severely restricted with H1N1 and H3N2 viral RNA not detectable in culture supernatants for both the EP and CP viruses. A virus induced apoptosis in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine release Recommended composition of influenza virus vaccines for use in 2006-2007 influenza season.


id: cord-339070-jnmogy7s
author: Yang, Lin
title: Influenza associated mortality in the subtropics and tropics: Results from three Asian cities
date: 2011-11-08
extension: .txt
mime: text/plain
words: 3607
sentence: 135
flesch: 39
cache: cache/cord-339070-jnmogy7s.txt
txt: txt/cord-339070-jnmogy7s.txt
summary:
  To our best knowledge, this is the first comparative study between Asian subtropical and tropical cities for influenza disease burden. However, geographical variations in influenza associated disease burden in the tropics and subtropics have not been explored.


id: cord-324911-6s7ubbxl
author: Drury, Georgina
date: 2019-04-17
extension: .txt
mime: text/plain
words: 5387
sentence: 208
flesch: 35
cache: cache/cord-324911-6s7ubbxl.txt
txt: txt/cord-324911-6s7ubbxl.txt
title:
  Process mapping of vaccines: Understanding the limitations in current response to emerging epidemic threats

summary:
  As part of their work, the network commissioned the creation of a Vaccine Development Tool (http://www.vaccinedevelopment.org.uk/) to serve as a guide to the key stages in vaccine development. WG3: To understand the challenges in vaccine development and the key rate limiting steps for any given vaccine in development.


id: cord-321901-zpi7uis1
author: Roberts, Anjeanette
date: 2006-11-30
extension: .txt
mime: text/plain
words: 6604
sentence: 262
flesch: 36
cache: cache/cord-321901-zpi7uis1.txt
txt: txt/cord-321901-zpi7uis1.txt
title:
  Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK

summary:
  Severe acute respiratory syndrome WHO investigates China's fall in SARS cases WHO says SARS outbreak is over, but fight should go on Summary of probable SARS cases with onset of illness from 1 Identification of a novel coronavirus in patients with severe acute respiratory syndrome Coronavirus as a possible cause of severe acute respiratory syndrome Characterization of a novel coronavirus associated with severe acute respiratory syndrome Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage The Genome sequence of the SARS-associated coronavirus SARS coronavirus: a new challenge for prevention and therapy Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China The aetiology, origins, and diagnosis of severe acute respiratory syndrome Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Adaptation of SARS coronavirus to humans Bats are natural reservoirs of SARS-like coronaviruses Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus SARS immunity and vaccination Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans Virology: SARS virus infection of cats and ferrets Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters Koch's postulates fulfilled for SARS virus Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome Effects of a SARS-associated coronavirus vaccine in monkeys Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Macaque model for severe acute respiratory syndrome An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates Infection of SARS-CoV on juvenile and adult Brandt's vole Microtus brandtii Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice Immunogenicity of SARS inactivated vaccine in BALB/c mice Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses Antibody-dependent enhancement of virus infection and disease Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus Laboratory Biosafety Manual WHO biosafety guidelines for handling of SARS specimens Caution urged on SARS vaccines The authors thank Dr. Marc P. Girard and Dr. Marie-Paule Kieny for their invaluable assistance in preparing the manuscript.


id: cord-354818-yf5lvbs1
author: von Linstow, Marie-Louise
date: 2020-08-13
extension: .txt
mime: text/plain
words: 4049
sentence: 176
flesch: 44
cache: cache/cord-354818-yf5lvbs1.txt
txt: txt/cord-354818-yf5lvbs1.txt
title:
  Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

summary:
  Only 37.8% was in favour of mandatory influenza vaccination. However, the findings that just over half of those supporting the idea of mandatory influenza vaccination were vaccinated themselves, could lead to the assumption that some workers stating they would accept vaccination, would in reality not.


id: cord-341970-pho6dksc
author: Huang, Jun
title: Immunization with SARS-CoV S DNA vaccine generates memory CD4(+) and CD8(+) T cell immune responses
date: 2006-06-05
extension: .txt
mime: text/plain
words: 4440
sentence: 181
flesch: 56
cache: cache/cord-341970-pho6dksc.txt
txt: txt/cord-341970-pho6dksc.txt
summary:
  Distinct populations of SARS-CoV S specific IFN-␥ and IL-2-producing CD4 + and CD8 + T cells are persistent in lymphoid and non-lymphoid organs following prime and boost DNA vaccination. As shown in Fig. 2B , IL-2 + cells were detected in CD4 + T cells but very few IL-2-producing cells were detected in CD8 + T cells.


id: cord-341626-04svm6le
author: Assink, M.D.M.
date: 2009-02-11
extension: .txt
mime: text/plain
words: 5667
sentence: 231
flesch: 40
cache: cache/cord-341626-04svm6le.txt
txt: txt/cord-341626-04svm6le.txt
title:
  Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination

summary:
  Infant and children seasonal immunisation against influenza on a routine basis during inter-pandemic period Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review Influenza vaccines in healthy children Influenza vaccines in healthy children Immunopathology of RSV infection: prospects for developing vaccines without this complication The use of health economics to guide drug development decisions: determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk Mortality in children from influenza and respiratory syncytial virus Respiratory syncytial virus or influenza? Respiratory syncytial virus infection in elderly adults Influenza-and RSV-associated hospitalizations among adults Influenza-and respiratory syncytial virus-associated mortality and hospitalisations Respiratory illness associated with influenza and respiratory syncytial virus infection The causes and diagnosis of influenza-like illness Incidence of influenza and associated illness in children aged 0-19 years: a systematic review Respiratory viruses and influenza-like illness: a survey in the area of Rome Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial Influenza vaccination in the prevention of acute otitis media in children NHG-Standaard Otitis media acuta bij kinderen (M09) Prevalence of various respiratory viruses in the middle ear during acute otitis media Role of respiratory viruses in children with acute otitis media Primary care management of respiratory tract infections in Dutch preschool children Influenza-and respiratory syncytial virus-associated morbidity and mortality in the nursing home population Association of influenza vaccination and reduced risk of recurrent myocardial infarction Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly Epidemiological studies: a practical guide Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods Influenza and respiratory syncytial virus morbidity among 0-19 aged group in Yunus Emre Health Center Mortality associated with influenza and respiratory syncytial virus in the United States Contribution of respiratory syncytial virus, influenza and parainfluenza viruses to acute respiratory infections in Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children Winter viruses: influenza-and respiratory syncytial virus-related morbidity in chronic lung disease In contrast to antibiotics, excess prescriptions were higher during influenza periods than during RSV periods.


id: cord-346032-188gnf8j
author: Cheung, Ying-Kit
date: 2007-08-10
extension: .txt
mime: text/plain
words: 4776
sentence: 134
flesch: 38
cache: cache/cord-346032-188gnf8j.txt
txt: txt/cord-346032-188gnf8j.txt
title:
  Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope

summary:
  The N-protein transduced N/E6E7/2.1K b cells were used as target cells. The spontaneous release of LDH by target cells or effector cells The full-length amino acid sequence of the SARS N-protein was subjected to bioinformatic analysis to search for HLA-A*0201 restricted nine-amino acid peptides.


id: cord-345658-u9vgycib
author: Volkmann, Ariane
date: 2020-10-17
extension: .txt
mime: text/plain
words: 4654
sentence: 136
flesch: 24
cache: cache/cord-345658-u9vgycib.txt
txt: txt/cord-345658-u9vgycib.txt
title:
  The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

summary:
  Guidance for clinicians Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses -recommendations of the Advisory Committee on Immunization Practices (ACIP) Spread of vaccinia virus through shaving during military training Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects Safety and immunogenicity of modified vaccinia ankara-bavarian nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virusinfected individuals: an open-label, controlled clinical Phase II Trial A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS A Phase 1 dose escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules Phase I trial of a modified vaccinia ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis A multicenter, open-label, controlled Phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18-40 year old subjects with diagnosed atopic dermatitis Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial A comparative Phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes Immunogenicity of a novel Clade B HIV-1 vaccine combination: results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSFexpressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization Safety and immunogenicity of PENNVAX-G DNA prime administered by biojector 2000 or CELLECTRA electroporation device with modified Vaccinia Ankara-CMDR boost Subtype C gp140 vaccine boosts immune responses primed by the South African AIDS vaccine initiative DNA-C2 and MVA-C HIV vaccines after more than a 2-Year Gap A randomized, double-blind, placebo-controlled Phase II trial investigating the safety and immunogenicity of modified Vaccinia Ankara smallpox vaccine (MVA-BN(R)) in 56-80-year-old subjects Vaccine xxx (xxxx) xxx Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a Phase I trial Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario Phase II randomized, double-blinded comparison of a single high dose (5x10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1x10(8) TCID50) in healthy vaccinia-naive individuals Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: a randomized clinical non-inferiority trial Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses Construction and biological characteristic for the recombinant modified vaccinia virus ankara co-expressing modified GP5 and M protein of porcine reproductive and respiratory syndrome virus Genetic stability of recombinant MVA-BN A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates Broad antibody and cellular immune response from a Phase 2 clinical trial with a novel multivalent poxvirus based RSV vaccine Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus Environmental resistance, disinfection, and sterilization of poxviruses Rapid protection in a monkeypox model by a single injection of a replicationdeficient vaccinia virus Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection Immunogenicity and protection after vaccination with a modified Vaccinia virus Ankara-vectored yellow fever vaccine in the hamster model Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children Safety and efficacy of novel malaria vaccine regimens of RTS, S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice Smallpox and Monkeypox Vaccine, Live, Nonreplicating) Prescribing Information Vaccinating against monkeypox in the Democratic Republic of the Congo Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine ''MVA


id: cord-265757-8ces57rn
author: Tondella, M. L.
date: 2009-02-05
extension: .txt
mime: text/plain
words: 11139
sentence: 428
flesch: 36
cache: cache/cord-265757-8ces57rn.txt
txt: txt/cord-265757-8ces57rn.txt
title:
  International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007

summary:
  Possible reasons for the resurgence of reported pertussis are (1) greater awareness of pertussis; (2) waning of vaccine-induced immunity; (3) lessened potency of pertussis vaccines; (4) genetic changes in B. pertussis; and (5) the general availability of better laboratory tests for the diagnosis of pertussis. Since most individuals had been exposed to pertussis vaccine or infection, the study focused on an estimation of the incidence of recent infections, as defined by the presence of IgG anti-PT antibodies above defined thresholds


id: cord-340686-uq0fsqh3
author: Dwivedi, Varun
date: 2011-05-23
extension: .txt
mime: text/plain
words: 6484
sentence: 233
flesch: 37
cache: cache/cord-340686-uq0fsqh3.txt
txt: txt/cord-340686-uq0fsqh3.txt
title:
  Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs

summary:
  The mucosal immune system is modulated by a variety of mechanisms involving innate immune cells such as DCs, NK cells, and mast cells which contribute significantly to host defense against pathogens Nasopharyngeal lymphoid tissues contain the entire repertoire of immune cells and are strategically located to orchestrate regional immune functions against airborne infections [16] .


id: cord-348218-wyy4rvqb
author: Ashwell, Douglas
date: 2020-07-09
extension: .txt
mime: text/plain
words: 5992
sentence: 239
flesch: 41
cache: cache/cord-348218-wyy4rvqb.txt
txt: txt/cord-348218-wyy4rvqb.txt
title:
  When being positive might be negative: An analysis of Australian and New Zealand newspaper framing of vaccination post Australia's No Jab No Pay legislation

summary:
  Differences were found in the sources most prevalent in vaccination stories between the two countries. The news media play a vital role in communicating vaccination messages to the public [27, 23] .


id: cord-342831-4qfe8kok
author: Xia, Yufei
title: Chitosan-based mucosal adjuvants: Sunrise on the ocean
date: 2015-11-04
extension: .txt
mime: text/plain
words: 7879
sentence: 277
flesch: 31
cache: cache/cord-342831-4qfe8kok.txt
txt: txt/cord-342831-4qfe8kok.txt
summary:
  In vitro permeability across Caco-2 Cells (Colonic) can predict in vivo (small intestinal) absorption in man-fact or myth Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes Oral delivery of peptide drugs using nanoparticles self-assembled by poly(gamma-glutamic acid) and a chitosan derivative functionalized by trimethylation Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice Preparation and evaluation of chitosan nanoparticles containing Diphtheria toxoid as new carriers for nasal vaccine delivery in mice N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles Development and characterization of chitosan coated poly-(varepsilon-caprolactone) nanoparticulate system for effective immunization against influenza In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice Chitosan chemistry and pharmaceutical perspectives Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system pH-sensitive and mucoadhesive thiolated Eudragit-coated chitosan microspheres Formulation, characterization and optimization of Hepatitis B surface antigen (HBsAg)-loaded chitosan microspheres for oral delivery Bioadhesive-based dosage forms: the next generation Chitosan as a novel nasal delivery system for vaccines Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules Chitosan GRAS notice Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A Human susceptibility and resistance to Norwalk virus infection Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues Norovirus vaccine against experimental human Norwalk virus illness Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers The significance of mucosal immunity and its potential for improving global health has inspired research demonstrating that mucosal vaccines could be an attractive alternative to parenteral administration [6, 7] .


id: cord-318407-uy0f7f2o
author: Nara, Peter L.
date: 2008-11-18
extension: .txt
mime: text/plain
words: 12532
sentence: 451
flesch: 37
cache: cache/cord-318407-uy0f7f2o.txt
txt: txt/cord-318407-uy0f7f2o.txt
title:
  Perspectives on advancing preventative medicine through vaccinology at the comparative veterinary, human and conservation medicine interface: Not missing the opportunities

summary:
  In addition vaccination along with other animal production changes has provided the ability to produce otherwise unaffordable animal protein and animal health worldwide. In addition vaccination along with other animal production changes has provided the ability to produce otherwise unaffordable animal protein and animal health worldwide.


# url

id: cord-324911-6s7ubbxl
domain: wellcome.ac.uk
url:
  https://wellcome.ac.uk/press-release/unprecedented-international-consortiumassembled-accelerate-collaborative-multi-site)


# pos

id: cord-324911-6s7ubbxl
sid: 22
tid: 25
pos: PROPN
token:
  https://wellcome.ac.uk/press-release/unprecedented-international-consortiumassembled-accelerate-collaborative-multi-site

lemma:
  https://wellcome.ac.uk/press-release/unprecedented-international-consortiumassembled-accelerate-collaborative-multi-site


